EA014556B1 - Производные ксантина в качестве селективных агонистов hm74a - Google Patents
Производные ксантина в качестве селективных агонистов hm74a Download PDFInfo
- Publication number
- EA014556B1 EA014556B1 EA200800555A EA200800555A EA014556B1 EA 014556 B1 EA014556 B1 EA 014556B1 EA 200800555 A EA200800555 A EA 200800555A EA 200800555 A EA200800555 A EA 200800555A EA 014556 B1 EA014556 B1 EA 014556B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- chloro
- mmol
- butyl
- dihydro
- propyl
- Prior art date
Links
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 title abstract description 8
- 239000000556 agonist Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 304
- 238000000034 method Methods 0.000 claims abstract description 100
- 238000011282 treatment Methods 0.000 claims abstract description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
- 238000004519 manufacturing process Methods 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- -1 2-pyridinyl Chemical group 0.000 claims description 299
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 139
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 135
- 229910052757 nitrogen Inorganic materials 0.000 claims description 66
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 60
- 150000003839 salts Chemical class 0.000 claims description 39
- 125000003118 aryl group Chemical group 0.000 claims description 30
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 27
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 27
- 125000001072 heteroaryl group Chemical group 0.000 claims description 27
- 229910052736 halogen Inorganic materials 0.000 claims description 21
- 150000002367 halogens Chemical class 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 17
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 17
- 125000002947 alkylene group Chemical group 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 230000029936 alkylation Effects 0.000 claims description 15
- 238000005804 alkylation reaction Methods 0.000 claims description 15
- 201000001320 Atherosclerosis Diseases 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 13
- 229920006395 saturated elastomer Polymers 0.000 claims description 13
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 12
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 claims description 12
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 12
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 11
- 206010021024 Hypolipidaemia Diseases 0.000 claims description 11
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 11
- 208000029078 coronary artery disease Diseases 0.000 claims description 11
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 11
- 208000026621 hypolipoproteinemia Diseases 0.000 claims description 11
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 10
- 206010019280 Heart failures Diseases 0.000 claims description 10
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 10
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 10
- 206010022489 Insulin Resistance Diseases 0.000 claims description 10
- 208000008589 Obesity Diseases 0.000 claims description 10
- 125000002950 monocyclic group Chemical group 0.000 claims description 10
- 235000020824 obesity Nutrition 0.000 claims description 10
- 208000007536 Thrombosis Diseases 0.000 claims description 9
- 206010002383 Angina Pectoris Diseases 0.000 claims description 8
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 8
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 8
- 125000002619 bicyclic group Chemical group 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 7
- 208000020832 chronic kidney disease Diseases 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 229940075420 xanthine Drugs 0.000 claims description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- 230000026030 halogenation Effects 0.000 claims description 5
- 238000005658 halogenation reaction Methods 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 125000006239 protecting group Chemical group 0.000 claims description 5
- 150000003536 tetrazoles Chemical group 0.000 claims description 5
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 4
- 238000010511 deprotection reaction Methods 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- VEEPFOJGVUXDRX-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[5-[(4-fluorophenyl)methyl]tetrazol-2-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCN(N=1)N=NC=1CC1=CC=C(F)C=C1 VEEPFOJGVUXDRX-UHFFFAOYSA-N 0.000 claims description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 1
- 102100030643 Hydroxycarboxylic acid receptor 2 Human genes 0.000 abstract description 20
- 101000843809 Homo sapiens Hydroxycarboxylic acid receptor 2 Proteins 0.000 abstract description 19
- 102000005962 receptors Human genes 0.000 abstract description 13
- 108020003175 receptors Proteins 0.000 abstract description 13
- 230000004913 activation Effects 0.000 abstract description 9
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 308
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 304
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 158
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 149
- 238000001819 mass spectrum Methods 0.000 description 145
- 239000000243 solution Substances 0.000 description 136
- 239000007787 solid Substances 0.000 description 121
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 80
- 239000000047 product Substances 0.000 description 76
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 74
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 72
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 61
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 53
- 239000012044 organic layer Substances 0.000 description 47
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 46
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 43
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 40
- 239000011541 reaction mixture Substances 0.000 description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- 239000012267 brine Substances 0.000 description 37
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 36
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 35
- 239000012074 organic phase Substances 0.000 description 35
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 34
- 238000003756 stirring Methods 0.000 description 33
- 238000000746 purification Methods 0.000 description 31
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 31
- 239000012043 crude product Substances 0.000 description 29
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 29
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 26
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 23
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 22
- 239000003921 oil Substances 0.000 description 22
- 235000019198 oils Nutrition 0.000 description 22
- 239000002585 base Substances 0.000 description 20
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 20
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 20
- 239000000843 powder Substances 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 19
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 239000011664 nicotinic acid Substances 0.000 description 18
- 229960003512 nicotinic acid Drugs 0.000 description 18
- 235000001968 nicotinic acid Nutrition 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- 229910017976 MgO 4 Inorganic materials 0.000 description 17
- 239000000377 silicon dioxide Substances 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- CGNXDNSPHUBQDH-UHFFFAOYSA-N 3-butyl-8-chloro-1-[4-(5-pyridin-2-yl-1,2,4-oxadiazol-3-yl)butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(N=1)=NOC=1C1=CC=CC=N1 CGNXDNSPHUBQDH-UHFFFAOYSA-N 0.000 description 16
- 238000001816 cooling Methods 0.000 description 16
- FAIAJSOSTNJZCI-UHFFFAOYSA-N purine-2,6-dione Chemical group O=C1NC(=O)C2=NC=NC2=N1 FAIAJSOSTNJZCI-UHFFFAOYSA-N 0.000 description 16
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 239000012535 impurity Substances 0.000 description 14
- 229910000027 potassium carbonate Inorganic materials 0.000 description 13
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 12
- UEHBSOZKEHODBZ-UHFFFAOYSA-N 3-butyl-8-chloro-7-prop-2-enylpurine-2,6-dione Chemical compound O=C1NC(=O)N(CCCC)C2=C1N(CC=C)C(Cl)=N2 UEHBSOZKEHODBZ-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 238000010828 elution Methods 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 239000012299 nitrogen atmosphere Substances 0.000 description 12
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 11
- 239000008346 aqueous phase Substances 0.000 description 11
- 239000000543 intermediate Substances 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- 229910000029 sodium carbonate Inorganic materials 0.000 description 11
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 11
- 102100039356 Hydroxycarboxylic acid receptor 3 Human genes 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- ZXSNABHDRKDSMU-UHFFFAOYSA-N ethyl 4-(3-butyl-8-chloro-2,6-dioxo-7h-purin-1-yl)butanoate Chemical compound O=C1N(CCCC(=O)OCC)C(=O)N(CCCC)C2=C1NC(Cl)=N2 ZXSNABHDRKDSMU-UHFFFAOYSA-N 0.000 description 10
- GXHFUVWIGNLZSC-UHFFFAOYSA-N meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 description 10
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- 239000010802 sludge Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- WTUVPERXQXSPFE-UHFFFAOYSA-N 8-chloro-3-pentyl-7-prop-2-enylpurine-2,6-dione Chemical compound O=C1NC(=O)N(CCCCC)C2=C1N(CC=C)C(Cl)=N2 WTUVPERXQXSPFE-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 101001035752 Homo sapiens Hydroxycarboxylic acid receptor 3 Proteins 0.000 description 9
- 239000011230 binding agent Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- 101000587820 Homo sapiens Selenide, water dikinase 1 Proteins 0.000 description 7
- 102100031163 Selenide, water dikinase 1 Human genes 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 238000004140 cleaning Methods 0.000 description 7
- 239000012230 colorless oil Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 208000030159 metabolic disease Diseases 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 101000701815 Homo sapiens Spermidine synthase Proteins 0.000 description 6
- 208000018262 Peripheral vascular disease Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 6
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 208000027866 inflammatory disease Diseases 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 150000002825 nitriles Chemical class 0.000 description 6
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- WPTWHVQNBTXLFA-UHFFFAOYSA-N 2-(3-chloropropyl)-5-[(2,4-difluorophenyl)methyl]-1,3,4-oxadiazole Chemical compound FC1=CC(F)=CC=C1CC1=NN=C(CCCCl)O1 WPTWHVQNBTXLFA-UHFFFAOYSA-N 0.000 description 5
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 5
- KULPEMIOTUCHSD-UHFFFAOYSA-N 3-(3-benzyl-1,2,4-oxadiazol-5-yl)propan-1-ol Chemical compound O1C(CCCO)=NC(CC=2C=CC=CC=2)=N1 KULPEMIOTUCHSD-UHFFFAOYSA-N 0.000 description 5
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 5
- KOZZYIHVPUEIPB-UHFFFAOYSA-N 8-chloro-7-prop-2-enyl-3h-purine-2,6-dione Chemical compound N1C(=O)NC(=O)C2=C1N=C(Cl)N2CC=C KOZZYIHVPUEIPB-UHFFFAOYSA-N 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- 229920004518 DION® Polymers 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- IRJKSAIGIYODAN-ISLYRVAYSA-N benzyl (ne)-n-phenylmethoxycarbonyliminocarbamate Chemical compound C=1C=CC=CC=1COC(=O)/N=N/C(=O)OCC1=CC=CC=C1 IRJKSAIGIYODAN-ISLYRVAYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- SIQPXVQCUCHWDI-UHFFFAOYSA-N enprofylline Chemical compound O=C1NC(=O)N(CCC)C2=C1NC=N2 SIQPXVQCUCHWDI-UHFFFAOYSA-N 0.000 description 5
- YJOZWHPTJFCSEC-UHFFFAOYSA-N ethyl 5-(3-butyl-8-chloro-2,6-dioxo-7h-purin-1-yl)pentanoate Chemical compound O=C1N(CCCCC(=O)OCC)C(=O)N(CCCC)C2=C1NC(Cl)=N2 YJOZWHPTJFCSEC-UHFFFAOYSA-N 0.000 description 5
- MYZJTONHQMUXGQ-UHFFFAOYSA-N ethyl 5-(8-chloro-2,6-dioxo-3-pentyl-7h-purin-1-yl)pentanoate Chemical compound O=C1N(CCCCC(=O)OCC)C(=O)N(CCCCC)C2=C1NC(Cl)=N2 MYZJTONHQMUXGQ-UHFFFAOYSA-N 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 125000001207 fluorophenyl group Chemical group 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- HSCHZTCTGIIVMF-UHFFFAOYSA-N 3-(5-benzyl-1,2,4-oxadiazol-3-yl)propan-1-ol Chemical compound OCCCC1=NOC(CC=2C=CC=CC=2)=N1 HSCHZTCTGIIVMF-UHFFFAOYSA-N 0.000 description 4
- WUCJWETVLZKYSR-UHFFFAOYSA-N 3-butyl-8-chloro-1-[4-(3-phenyl-1,2-oxazol-5-yl)butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(ON=1)=CC=1C1=CC=CC=C1 WUCJWETVLZKYSR-UHFFFAOYSA-N 0.000 description 4
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 4
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 4
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- AMAVYZDBOIRNNM-UHFFFAOYSA-N 8-chloro-3-pentyl-7-prop-2-enyl-1-[3-(1h-pyrazol-4-yl)propyl]purine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)N(CC=C)C=2C(=O)N1CCCC=1C=NNC=1 AMAVYZDBOIRNNM-UHFFFAOYSA-N 0.000 description 4
- 244000215068 Acacia senegal Species 0.000 description 4
- OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical compound CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 229920000084 Gum arabic Polymers 0.000 description 4
- SIOXPEMLGUPBBT-UHFFFAOYSA-N Picolinic acid Natural products OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 239000000205 acacia gum Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000013058 crude material Substances 0.000 description 4
- 238000000113 differential scanning calorimetry Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 4
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 3
- 125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 description 3
- YSRCXLROFNRHLU-UHFFFAOYSA-N 2-hydroxyethanimidamide Chemical compound NC(=N)CO YSRCXLROFNRHLU-UHFFFAOYSA-N 0.000 description 3
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 3
- DJYNZJOMFQEISA-UHFFFAOYSA-N 3-butyl-8-chloro-1-[4-(3-phenyl-1,2,4-oxadiazol-5-yl)butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(ON=1)=NC=1C1=CC=CC=C1 DJYNZJOMFQEISA-UHFFFAOYSA-N 0.000 description 3
- MHBWLFBRFFFVTI-UHFFFAOYSA-N 3-hydroxypyridine-2-carboximidamide Chemical compound NC(=N)c1ncccc1O MHBWLFBRFFFVTI-UHFFFAOYSA-N 0.000 description 3
- SNZWLOSRUSBLBV-UHFFFAOYSA-N 4-(3-phenyl-1,2-oxazol-5-yl)butan-1-ol Chemical compound O1C(CCCCO)=CC(C=2C=CC=CC=2)=N1 SNZWLOSRUSBLBV-UHFFFAOYSA-N 0.000 description 3
- CDIIZULDSLKBKV-UHFFFAOYSA-N 4-chlorobutanoyl chloride Chemical compound ClCCCC(Cl)=O CDIIZULDSLKBKV-UHFFFAOYSA-N 0.000 description 3
- LCFDYOGBKPHLRY-UHFFFAOYSA-N 5-(3-butyl-8-chloro-2,6-dioxo-7h-purin-1-yl)pentanoic acid Chemical compound O=C1N(CCCCC(O)=O)C(=O)N(CCCC)C2=C1NC(Cl)=N2 LCFDYOGBKPHLRY-UHFFFAOYSA-N 0.000 description 3
- QGLRQNCHMGTHCL-UHFFFAOYSA-N 5-(8-chloro-3-ethyl-2,6-dioxo-7h-purin-1-yl)pentanoic acid Chemical compound O=C1N(CCCCC(O)=O)C(=O)N(CC)C2=C1NC(Cl)=N2 QGLRQNCHMGTHCL-UHFFFAOYSA-N 0.000 description 3
- MLZZDSKRLJXNCK-UHFFFAOYSA-N 8-chloro-3-ethyl-7-prop-2-enylpurine-2,6-dione Chemical compound O=C1NC(=O)N(CC)C2=C1N(CC=C)C(Cl)=N2 MLZZDSKRLJXNCK-UHFFFAOYSA-N 0.000 description 3
- RDJQLAINZZVEKX-UHFFFAOYSA-N 8-chloro-7-prop-2-enyl-3-propylpurine-2,6-dione Chemical compound O=C1NC(=O)N(CCC)C2=C1N(CC=C)C(Cl)=N2 RDJQLAINZZVEKX-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 230000006020 chronic inflammation Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- OCPARJDCKZYHRA-UHFFFAOYSA-N ethyl 5-(8-chloro-3-ethyl-2,6-dioxo-7h-purin-1-yl)pentanoate Chemical compound O=C1N(CCCCC(=O)OCC)C(=O)N(CC)C2=C1NC(Cl)=N2 OCPARJDCKZYHRA-UHFFFAOYSA-N 0.000 description 3
- AFRWBGJRWRHQOV-UHFFFAOYSA-N ethyl 5-bromopentanoate Chemical compound CCOC(=O)CCCCBr AFRWBGJRWRHQOV-UHFFFAOYSA-N 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 229940125753 fibrate Drugs 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000000634 powder X-ray diffraction Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000002594 sorbent Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000000825 ultraviolet detection Methods 0.000 description 3
- IYTUKSIOQKTZEG-UHFFFAOYSA-N (3-chloro-4-hydroxyphenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(O)C(Cl)=C1 IYTUKSIOQKTZEG-UHFFFAOYSA-N 0.000 description 2
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 2
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 2
- IBLMYGXJKQIGSN-UHFFFAOYSA-N 1-(bromomethyl)-2,4-difluorobenzene Chemical compound FC1=CC=C(CBr)C(F)=C1 IBLMYGXJKQIGSN-UHFFFAOYSA-N 0.000 description 2
- SUGKYOPVPUZUAO-UHFFFAOYSA-N 1-[3-(1-benzylimidazol-4-yl)propyl]-3-butyl-8-chloro-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(N=C1)=CN1CC1=CC=CC=C1 SUGKYOPVPUZUAO-UHFFFAOYSA-N 0.000 description 2
- MYLOVBNPSLZRAN-UHFFFAOYSA-N 1-benzyl-3-(4-bromobutyl)pyrrolidin-2-one Chemical compound O=C1C(CCCCBr)CCN1CC1=CC=CC=C1 MYLOVBNPSLZRAN-UHFFFAOYSA-N 0.000 description 2
- WGSXKYXKAARAKD-UHFFFAOYSA-N 1-fluoro-3-isocyanato-5-(trifluoromethyl)benzene Chemical group FC1=CC(N=C=O)=CC(C(F)(F)F)=C1 WGSXKYXKAARAKD-UHFFFAOYSA-N 0.000 description 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 2
- UDWLEGFCVKEEHS-UHFFFAOYSA-N 2-(2,4-difluorophenyl)acetohydrazide Chemical compound NNC(=O)CC1=CC=C(F)C=C1F UDWLEGFCVKEEHS-UHFFFAOYSA-N 0.000 description 2
- PRASZCCYLWKZKA-UHFFFAOYSA-N 2-(2-chloro-4-fluorophenyl)acetohydrazide Chemical compound NNC(=O)CC1=CC=C(F)C=C1Cl PRASZCCYLWKZKA-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- HMECBJZDMWRPPO-UHFFFAOYSA-N 2-[(2-chloro-4-fluorophenyl)methyl]-5-(3-chloropropyl)-1,3,4-oxadiazole Chemical compound ClC1=CC(F)=CC=C1CC1=NN=C(CCCCl)O1 HMECBJZDMWRPPO-UHFFFAOYSA-N 0.000 description 2
- VKXRPIPVKNGPIJ-UHFFFAOYSA-N 2-benzyl-2-azaspiro[4.4]nonan-1-one Chemical compound C1CC2(CCCC2)C(=O)N1CC1=CC=CC=C1 VKXRPIPVKNGPIJ-UHFFFAOYSA-N 0.000 description 2
- HSXIRAAJATWTDW-UHFFFAOYSA-N 2-benzyl-5-(3-chloropropyl)-1,3,4-oxadiazole Chemical compound O1C(CCCCl)=NN=C1CC1=CC=CC=C1 HSXIRAAJATWTDW-UHFFFAOYSA-N 0.000 description 2
- YLMGUQOHXLAGMQ-UHFFFAOYSA-N 2-hydroxybutanimidamide Chemical compound CCC(O)C(N)=N YLMGUQOHXLAGMQ-UHFFFAOYSA-N 0.000 description 2
- KMSFGOSNSYQVGL-UHFFFAOYSA-N 2-pyridin-1-ium-1-ylpyridine Chemical compound C1=CC=CC=[N+]1C1=CC=CC=N1 KMSFGOSNSYQVGL-UHFFFAOYSA-N 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000004361 3,4,5-trifluorophenyl group Chemical group [H]C1=C(F)C(F)=C(F)C([H])=C1* 0.000 description 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 2
- SLRWBRGXUCSZOY-UHFFFAOYSA-N 3-(3-benzyl-1,2-oxazol-5-yl)propan-1-ol Chemical compound O1C(CCCO)=CC(CC=2C=CC=CC=2)=N1 SLRWBRGXUCSZOY-UHFFFAOYSA-N 0.000 description 2
- KDPHEWWOBFNAEN-UHFFFAOYSA-N 3-(3-butyl-8-chloro-2,6-dioxo-7-prop-2-enylpurin-1-yl)propyl methanesulfonate Chemical compound O=C1N(CCCOS(C)(=O)=O)C(=O)N(CCCC)C2=C1N(CC=C)C(Cl)=N2 KDPHEWWOBFNAEN-UHFFFAOYSA-N 0.000 description 2
- FVMLZQUZCSEUIG-UHFFFAOYSA-N 3-(5-benzyl-1,2,4-oxadiazol-3-yl)propanal Chemical compound O=CCCC1=NOC(CC=2C=CC=CC=2)=N1 FVMLZQUZCSEUIG-UHFFFAOYSA-N 0.000 description 2
- NVWZQVFMSTXSRL-UHFFFAOYSA-N 3-(8-chloro-2,6-dioxo-7-prop-2-enyl-3-propylpurin-1-yl)propyl methanesulfonate Chemical compound O=C1N(CCCOS(C)(=O)=O)C(=O)N(CCC)C2=C1N(CC=C)C(Cl)=N2 NVWZQVFMSTXSRL-UHFFFAOYSA-N 0.000 description 2
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 2
- LDWQMWNRESSHEP-UHFFFAOYSA-N 3-[3-[(4-chlorophenyl)methyl]-1,2,4-oxadiazol-5-yl]propan-1-ol Chemical compound O1C(CCCO)=NC(CC=2C=CC(Cl)=CC=2)=N1 LDWQMWNRESSHEP-UHFFFAOYSA-N 0.000 description 2
- GICZETZGAFPVMF-UHFFFAOYSA-N 3-[4-(8-chloro-3-pentyl-7,8-dihydro-2H-purin-1-yl)butyl]-5-phenyl-1,2,4-oxadiazole Chemical compound ClC1N=C2N(CN(C=C2N1)CCCCC1=NOC(=N1)C1=CC=CC=C1)CCCCC GICZETZGAFPVMF-UHFFFAOYSA-N 0.000 description 2
- NALUZVOMTHMLKZ-UHFFFAOYSA-N 3-[8-chloro-2,6-dioxo-7-prop-2-enyl-3-(4,4,4-trifluorobutyl)purin-1-yl]propyl methanesulfonate Chemical compound O=C1N(CCCOS(=O)(=O)C)C(=O)N(CCCC(F)(F)F)C2=C1N(CC=C)C(Cl)=N2 NALUZVOMTHMLKZ-UHFFFAOYSA-N 0.000 description 2
- DITNVHWVFHZLDT-UHFFFAOYSA-N 3-benzyl-1-(4-bromobutyl)pyrrolidin-2-one Chemical compound O=C1N(CCCCBr)CCC1CC1=CC=CC=C1 DITNVHWVFHZLDT-UHFFFAOYSA-N 0.000 description 2
- LLTBHZANIPKEGJ-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[3-[(4-chlorophenyl)methyl]-1,2,4-oxadiazol-5-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(ON=1)=NC=1CC1=CC=C(Cl)C=C1 LLTBHZANIPKEGJ-UHFFFAOYSA-N 0.000 description 2
- NZUWOXLMZMDXDS-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[5-[(3-fluorophenyl)methyl]tetrazol-2-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCN(N=1)N=NC=1CC1=CC=CC(F)=C1 NZUWOXLMZMDXDS-UHFFFAOYSA-N 0.000 description 2
- YDBWUUQDWKSJQS-UHFFFAOYSA-N 4-(3-butyl-8-chloro-2,6-dioxo-7-prop-2-enylpurin-1-yl)butanenitrile Chemical compound O=C1N(CCCC#N)C(=O)N(CCCC)C2=C1N(CC=C)C(Cl)=N2 YDBWUUQDWKSJQS-UHFFFAOYSA-N 0.000 description 2
- BLAQJGZIXWZQOD-UHFFFAOYSA-N 4-(3-butyl-8-chloro-2,6-dioxo-7h-purin-1-yl)butanenitrile Chemical compound O=C1N(CCCC#N)C(=O)N(CCCC)C2=C1NC(Cl)=N2 BLAQJGZIXWZQOD-UHFFFAOYSA-N 0.000 description 2
- RNOVGJWJVRESAA-UHFFFAOYSA-N 4-fluoro-2-(trifluoromethyl)phenol Chemical group OC1=CC=C(F)C=C1C(F)(F)F RNOVGJWJVRESAA-UHFFFAOYSA-N 0.000 description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 2
- VZUXJKUZRQUUMU-UHFFFAOYSA-N 5-(3-butyl-8-chloro-2,6-dioxo-7h-purin-1-yl)pentanenitrile Chemical compound O=C1N(CCCCC#N)C(=O)N(CCCC)C2=C1NC(Cl)=N2 VZUXJKUZRQUUMU-UHFFFAOYSA-N 0.000 description 2
- JDPCFNUQAFMWSH-UHFFFAOYSA-N 5-[(4-fluorophenyl)methyl]-2h-tetrazole Chemical compound C1=CC(F)=CC=C1CC1=NNN=N1 JDPCFNUQAFMWSH-UHFFFAOYSA-N 0.000 description 2
- ZXXRFEWIVJPFQF-UHFFFAOYSA-N 5-benzyl-2-(3-bromopropyl)tetrazole Chemical compound BrCCCN1N=NC(CC=2C=CC=CC=2)=N1 ZXXRFEWIVJPFQF-UHFFFAOYSA-N 0.000 description 2
- HHDRWGJJZGJSGZ-UHFFFAOYSA-N 5-benzyl-2h-tetrazole Chemical compound C=1C=CC=CC=1CC=1N=NNN=1 HHDRWGJJZGJSGZ-UHFFFAOYSA-N 0.000 description 2
- NWWWGAKVHCSAEU-UHFFFAOYSA-N 5-bromopentanenitrile Chemical compound BrCCCCC#N NWWWGAKVHCSAEU-UHFFFAOYSA-N 0.000 description 2
- CGRRUFNHHQCLDZ-UHFFFAOYSA-N 5-hydroxypyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(O)C=N1 CGRRUFNHHQCLDZ-UHFFFAOYSA-N 0.000 description 2
- JRGZDXWJUBEPRD-UHFFFAOYSA-N 8-chloro-1-(3-hydroxypropyl)-7-prop-2-enyl-3-propylpurine-2,6-dione Chemical compound O=C1N(CCCO)C(=O)N(CCC)C2=C1N(CC=C)C(Cl)=N2 JRGZDXWJUBEPRD-UHFFFAOYSA-N 0.000 description 2
- KLXQEBIACABGID-UHFFFAOYSA-N 8-chloro-1-[3-[1-[(2,4-difluorophenyl)methyl]pyrazol-4-yl]propyl]-3-pentyl-7h-purine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(=C1)C=NN1CC1=CC=C(F)C=C1F KLXQEBIACABGID-UHFFFAOYSA-N 0.000 description 2
- QBGKAZMXKZJNBO-UHFFFAOYSA-N 8-chloro-1-[3-[1-[(2-chloro-6-fluorophenyl)methyl]pyrazol-4-yl]propyl]-3-pentyl-7h-purine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(=C1)C=NN1CC1=C(F)C=CC=C1Cl QBGKAZMXKZJNBO-UHFFFAOYSA-N 0.000 description 2
- RVYURXGZJFKLNP-UHFFFAOYSA-N 8-chloro-1-[3-[5-[(4-fluorophenyl)methyl]tetrazol-2-yl]propyl]-3-(4,4,4-trifluorobutyl)-7h-purine-2,6-dione Chemical compound C1=CC(F)=CC=C1CC1=NN(CCCN2C(C=3NC(Cl)=NC=3N(CCCC(F)(F)F)C2=O)=O)N=N1 RVYURXGZJFKLNP-UHFFFAOYSA-N 0.000 description 2
- FDVZYKZTMMSQMC-UHFFFAOYSA-N 8-chloro-1-[5-[5-[(3,4-dichlorophenyl)methyl]tetrazol-2-yl]pentyl]-3-pentyl-7h-purine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCCN(N=1)N=NC=1CC1=CC=C(Cl)C(Cl)=C1 FDVZYKZTMMSQMC-UHFFFAOYSA-N 0.000 description 2
- DKKNLFNLJYVNGH-UHFFFAOYSA-N 8-chloro-3-(3-cyclopropylpropyl)-7-prop-2-enylpurine-2,6-dione Chemical compound O=C1NC(=O)C=2N(CC=C)C(Cl)=NC=2N1CCCC1CC1 DKKNLFNLJYVNGH-UHFFFAOYSA-N 0.000 description 2
- WQCIPKJYZUAHCX-UHFFFAOYSA-N 8-chloro-7-prop-2-enyl-1-[4-(3-pyridin-2-yl-1,2,4-oxadiazol-5-yl)butyl]-3h-purine-2,6-dione Chemical compound O=C1C=2N(CC=C)C(Cl)=NC=2NC(=O)N1CCCCC(ON=1)=NC=1C1=CC=CC=N1 WQCIPKJYZUAHCX-UHFFFAOYSA-N 0.000 description 2
- ZXVBJNLBSNPDQP-UHFFFAOYSA-N 8-chloro-7-prop-2-enyl-3-(4,4,4-trifluorobutyl)purine-2,6-dione Chemical compound O=C1NC(=O)N(CCCC(F)(F)F)C2=C1N(CC=C)C(Cl)=N2 ZXVBJNLBSNPDQP-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 2
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 2
- 229940063655 aluminum stearate Drugs 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- MXOQNVMDKHLYCZ-UHFFFAOYSA-N benzamidoxime Chemical compound ON=C(N)C1=CC=CC=C1 MXOQNVMDKHLYCZ-UHFFFAOYSA-N 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 2
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 2
- 238000002050 diffraction method Methods 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- YPKNBCCBUPHOEY-UHFFFAOYSA-N ethyl 4-(8-chloro-2,6-dioxo-3-pentyl-7h-purin-1-yl)butanoate Chemical compound O=C1N(CCCC(=O)OCC)C(=O)N(CCCCC)C2=C1NC(Cl)=N2 YPKNBCCBUPHOEY-UHFFFAOYSA-N 0.000 description 2
- OHDMYEJJKAVUOA-UHFFFAOYSA-N ethyl 4-(8-chloro-2,6-dioxo-7-prop-2-enyl-3h-purin-1-yl)butanoate Chemical compound O=C1N(CCCC(=O)OCC)C(=O)NC2=C1N(CC=C)C(Cl)=N2 OHDMYEJJKAVUOA-UHFFFAOYSA-N 0.000 description 2
- XBPOBCXHALHJFP-UHFFFAOYSA-N ethyl 4-bromobutanoate Chemical compound CCOC(=O)CCCBr XBPOBCXHALHJFP-UHFFFAOYSA-N 0.000 description 2
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N isopropyl alcohol Natural products CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 210000000944 nerve tissue Anatomy 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000002687 nonaqueous vehicle Substances 0.000 description 2
- 150000005830 nonesterified fatty acids Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229940068917 polyethylene glycols Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 229910052814 silicon oxide Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- IDXGPFZWEFSHCY-UHFFFAOYSA-N tert-butyl n-[[2-(2,4-difluorophenyl)acetyl]amino]carbamate Chemical compound CC(C)(C)OC(=O)NNC(=O)CC1=CC=C(F)C=C1F IDXGPFZWEFSHCY-UHFFFAOYSA-N 0.000 description 2
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 2
- VXKWYPOMXBVZSJ-UHFFFAOYSA-N tetramethyltin Chemical compound C[Sn](C)(C)C VXKWYPOMXBVZSJ-UHFFFAOYSA-N 0.000 description 2
- 125000004523 tetrazol-1-yl group Chemical group N1(N=NN=C1)* 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- PLYRYAHDNXANEG-QMWPFBOUSA-N (2s,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 PLYRYAHDNXANEG-QMWPFBOUSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 1
- PEUPUKDBCPLDIH-UHFFFAOYSA-N 1,2,4-triazole Chemical group C1=NC=N[N]1 PEUPUKDBCPLDIH-UHFFFAOYSA-N 0.000 description 1
- 125000004518 1,2,5-thiadiazol-3-yl group Chemical group S1N=C(C=N1)* 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- JLIDRDJNLAWIKT-UHFFFAOYSA-N 1,2-dimethyl-3h-benzo[e]indole Chemical compound C1=CC=CC2=C(C(=C(C)N3)C)C3=CC=C21 JLIDRDJNLAWIKT-UHFFFAOYSA-N 0.000 description 1
- XRRDFIPYLFCYLU-UHFFFAOYSA-N 1,3,5-trimethylbenzene Chemical group [CH2]C1=CC(C)=CC(C)=C1 XRRDFIPYLFCYLU-UHFFFAOYSA-N 0.000 description 1
- PURSZYWBIQIANP-UHFFFAOYSA-N 1-(bromomethyl)-2-chlorobenzene Chemical compound ClC1=CC=CC=C1CBr PURSZYWBIQIANP-UHFFFAOYSA-N 0.000 description 1
- KQNBRMUBPRGXSL-UHFFFAOYSA-N 1-(bromomethyl)-4-chlorobenzene Chemical compound ClC1=CC=C(CBr)C=C1 KQNBRMUBPRGXSL-UHFFFAOYSA-N 0.000 description 1
- BBXDMCQDLOCXRA-UHFFFAOYSA-N 1-(chloromethyl)-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1CCl BBXDMCQDLOCXRA-UHFFFAOYSA-N 0.000 description 1
- XGASTRVQNVVYIZ-UHFFFAOYSA-N 1-(chloromethyl)-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(CCl)=C1 XGASTRVQNVVYIZ-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- ZHIFUNJCJDOTTH-UHFFFAOYSA-N 1-[3-(3-benzyl-1,2,4-oxadiazol-5-yl)propyl]-8-chloro-3,7-dihydropurine-2,6-dione Chemical compound O=C1C=2NC(Cl)=NC=2NC(=O)N1CCCC(ON=1)=NC=1CC1=CC=CC=C1 ZHIFUNJCJDOTTH-UHFFFAOYSA-N 0.000 description 1
- IVLGUKILPJJFNC-UHFFFAOYSA-N 1-[3-(3-benzyl-1,2,4-oxadiazol-5-yl)propyl]-8-chloro-3-ethyl-7h-purine-2,6-dione Chemical compound O=C1N(CC)C=2N=C(Cl)NC=2C(=O)N1CCCC(ON=1)=NC=1CC1=CC=CC=C1 IVLGUKILPJJFNC-UHFFFAOYSA-N 0.000 description 1
- POMPNPHRIIMVGL-UHFFFAOYSA-N 1-[3-(3-benzyl-1,2,4-triazol-1-yl)propyl]-3-butyl-8-chloro-7-prop-2-enylpurine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)N(CC=C)C=2C(=O)N1CCCN(N=1)C=NC=1CC1=CC=CC=C1 POMPNPHRIIMVGL-UHFFFAOYSA-N 0.000 description 1
- BNISVDPJBNOKCK-UHFFFAOYSA-N 1-[3-(3-benzyl-1,2-oxazol-5-yl)propyl]-3-butyl-8-chloro-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(ON=1)=CC=1CC1=CC=CC=C1 BNISVDPJBNOKCK-UHFFFAOYSA-N 0.000 description 1
- WQBKKSGLGWSGBS-UHFFFAOYSA-N 1-[3-(4-benzylpiperazin-1-yl)propyl]-3-butyl-8-chloro-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCN(CC1)CCN1CC1=CC=CC=C1 WQBKKSGLGWSGBS-UHFFFAOYSA-N 0.000 description 1
- NBFKNBFCYVYIPU-UHFFFAOYSA-N 1-[3-(5-benzyl-1,2,4-oxadiazol-3-yl)propyl]-8-chloro-3-pentyl-7h-purine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(N=1)=NOC=1CC1=CC=CC=C1 NBFKNBFCYVYIPU-UHFFFAOYSA-N 0.000 description 1
- SHOPTPHRVFGHBY-UHFFFAOYSA-N 1-[3-(5-benzyl-1,2,4-oxadiazol-3-yl)propyl]-8-chloro-3-propyl-7h-purine-2,6-dione Chemical compound O=C1N(CCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(N=1)=NOC=1CC1=CC=CC=C1 SHOPTPHRVFGHBY-UHFFFAOYSA-N 0.000 description 1
- NOXQTKXKFQGYCA-UHFFFAOYSA-N 1-[3-[3-(7-bicyclo[4.2.0]octa-1,3,5-trienyl)-1,2,4-oxadiazol-5-yl]propyl]-3-butyl-8-chloro-7h-purine-2,6-dione Chemical compound C1C2=CC=CC=C2C1C1=NOC(CCCN2C(=O)C=3NC(Cl)=NC=3N(C2=O)CCCC)=N1 NOXQTKXKFQGYCA-UHFFFAOYSA-N 0.000 description 1
- LQVSJLUKOFCBLP-UHFFFAOYSA-N 1-[4-(1-benzyl-2-oxopyrrolidin-3-yl)butyl]-8-chloro-3-pentyl-7h-purine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(C1=O)CCN1CC1=CC=CC=C1 LQVSJLUKOFCBLP-UHFFFAOYSA-N 0.000 description 1
- SBNVRUQQGBUTAK-UHFFFAOYSA-N 1-[4-(3-benzyl-1,2,4-oxadiazol-5-yl)butyl]-3-butyl-8-chloro-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(ON=1)=NC=1CC1=CC=CC=C1 SBNVRUQQGBUTAK-UHFFFAOYSA-N 0.000 description 1
- LNFSJJNJYBNZMF-UHFFFAOYSA-N 1-[4-(3-benzyl-2-oxopyrrolidin-1-yl)butyl]-8-chloro-3-pentyl-7-prop-2-enylpurine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)N(CC=C)C=2C(=O)N1CCCCN(C1=O)CCC1CC1=CC=CC=C1 LNFSJJNJYBNZMF-UHFFFAOYSA-N 0.000 description 1
- IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical compound C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 description 1
- LVUQCTGSDJLWCE-UHFFFAOYSA-N 1-benzylpyrrolidin-2-one Chemical compound O=C1CCCN1CC1=CC=CC=C1 LVUQCTGSDJLWCE-UHFFFAOYSA-N 0.000 description 1
- ZCEAQTZIPVXWFA-UHFFFAOYSA-N 1-butyl-8-chloro-7-prop-2-enyl-3h-purine-2,6-dione Chemical compound O=C1N(CCCC)C(=O)NC2=C1N(CC=C)C(Cl)=N2 ZCEAQTZIPVXWFA-UHFFFAOYSA-N 0.000 description 1
- SFOYQZYQTQDRIY-UHFFFAOYSA-N 1-chloro-3-iodopropane Chemical compound ClCCCI SFOYQZYQTQDRIY-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- SBUXBHALPHVDFT-UHFFFAOYSA-N 1-methyltriazole-4-carboxylic acid Chemical compound CN1C=C(C(O)=O)N=N1 SBUXBHALPHVDFT-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FYYACQQSYSDVJB-UHFFFAOYSA-N 1-phenyl-2h-tetrazol-5-one Chemical compound OC1=NN=NN1C1=CC=CC=C1 FYYACQQSYSDVJB-UHFFFAOYSA-N 0.000 description 1
- KFOSBZWRVDQDJO-UHFFFAOYSA-N 1-phenylcyclopropane-1-carboximidamide Chemical compound C=1C=CC=CC=1C1(C(=N)N)CC1 KFOSBZWRVDQDJO-UHFFFAOYSA-N 0.000 description 1
- 125000000980 1H-indol-3-ylmethyl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[*])C2=C1[H] 0.000 description 1
- MWVMYAWMFTVYED-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C1CNCCC2=CC=CC=C21 MWVMYAWMFTVYED-UHFFFAOYSA-N 0.000 description 1
- WFNFKOIWDXLTJB-UHFFFAOYSA-N 2,4-difluoro-n'-hydroxybenzenecarboximidamide Chemical compound ON=C(N)C1=CC=C(F)C=C1F WFNFKOIWDXLTJB-UHFFFAOYSA-N 0.000 description 1
- ONOTYLMNTZNAQZ-UHFFFAOYSA-N 2,6-difluorobenzoic acid Chemical compound OC(=O)C1=C(F)C=CC=C1F ONOTYLMNTZNAQZ-UHFFFAOYSA-N 0.000 description 1
- IYRCHGRRMKOSHW-UHFFFAOYSA-N 2-(2,3-difluorophenyl)acetonitrile Chemical compound FC1=CC=CC(CC#N)=C1F IYRCHGRRMKOSHW-UHFFFAOYSA-N 0.000 description 1
- KRRSVTMKTCLBFZ-UHFFFAOYSA-N 2-(2-chloro-4-fluorophenyl)acetyl chloride Chemical compound FC1=CC=C(CC(Cl)=O)C(Cl)=C1 KRRSVTMKTCLBFZ-UHFFFAOYSA-N 0.000 description 1
- NYURPCOPWHJZOC-UHFFFAOYSA-N 2-(3-chloro-2-methoxyphenyl)acetic acid Chemical compound COC1=C(Cl)C=CC=C1CC(O)=O NYURPCOPWHJZOC-UHFFFAOYSA-N 0.000 description 1
- WFPMUFXQDKMVCO-UHFFFAOYSA-N 2-(3-chlorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Cl)=C1 WFPMUFXQDKMVCO-UHFFFAOYSA-N 0.000 description 1
- UZPMDURBLPFQGG-UHFFFAOYSA-N 2-(3-chloropropyl)-1,3,4-oxadiazole Chemical compound ClCCCC1=NN=CO1 UZPMDURBLPFQGG-UHFFFAOYSA-N 0.000 description 1
- YRFBZAHYMOSSGX-UHFFFAOYSA-N 2-(3-fluoro-4-hydroxyphenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(O)C(F)=C1 YRFBZAHYMOSSGX-UHFFFAOYSA-N 0.000 description 1
- JHQBLYITVCBGTO-UHFFFAOYSA-N 2-(4-fluorophenyl)acetonitrile Chemical compound FC1=CC=C(CC#N)C=C1 JHQBLYITVCBGTO-UHFFFAOYSA-N 0.000 description 1
- IGUVNNXFTDCASP-UHFFFAOYSA-N 2-(bromomethyl)-1-chloro-3-fluorobenzene Chemical compound FC1=CC=CC(Cl)=C1CBr IGUVNNXFTDCASP-UHFFFAOYSA-N 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- NZKANSJXJCILHS-UHFFFAOYSA-N 2-[[1-[2-(4-fluorophenyl)-2-oxoethyl]piperidin-4-yl]methyl]-3h-isoindol-1-one;dihydrate;hydrochloride Chemical compound O.O.Cl.C1=CC(F)=CC=C1C(=O)CN1CCC(CN2C(C3=CC=CC=C3C2)=O)CC1 NZKANSJXJCILHS-UHFFFAOYSA-N 0.000 description 1
- CIBGXJVJPZCMFX-UHFFFAOYSA-N 2-bromobutanenitrile Chemical compound CCC(Br)C#N CIBGXJVJPZCMFX-UHFFFAOYSA-N 0.000 description 1
- MQTKXCOGYOYAMW-UHFFFAOYSA-N 2-chloro-5-(chloromethyl)thiophene Chemical compound ClCC1=CC=C(Cl)S1 MQTKXCOGYOYAMW-UHFFFAOYSA-N 0.000 description 1
- XNTIGDVFBDJLTQ-UHFFFAOYSA-N 2-chloro-6-fluorobenzoic acid Chemical compound OC(=O)C1=C(F)C=CC=C1Cl XNTIGDVFBDJLTQ-UHFFFAOYSA-N 0.000 description 1
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 description 1
- NXWTWYULZRDBSA-UHFFFAOYSA-N 2-fluoro-4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1F NXWTWYULZRDBSA-UHFFFAOYSA-N 0.000 description 1
- NSTREUWFTAOOKS-UHFFFAOYSA-N 2-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1F NSTREUWFTAOOKS-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- OAVCSTVEAHLXPI-UHFFFAOYSA-N 2-hydroxy-2-phenylethanimidoyl chloride Chemical compound OC(C(Cl)=N)c1ccccc1 OAVCSTVEAHLXPI-UHFFFAOYSA-N 0.000 description 1
- MDLKFPDOGLWJFQ-UHFFFAOYSA-N 2-hydroxybenzenecarboximidoyl chloride Chemical compound Oc1ccccc1C(Cl)=N MDLKFPDOGLWJFQ-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- MKZCIVBMCPIMNP-UHFFFAOYSA-N 2-thiophen-3-ylethanimidamide Chemical compound NC(=N)CC=1C=CSC=1 MKZCIVBMCPIMNP-UHFFFAOYSA-N 0.000 description 1
- JTSRPXNPVLMJLB-UHFFFAOYSA-N 2H-pyridin-2-ide Chemical compound N1=[C-]C=CC=C1 JTSRPXNPVLMJLB-UHFFFAOYSA-N 0.000 description 1
- 125000006509 3,4-difluorobenzyl group Chemical group [H]C1=C(F)C(F)=C([H])C(=C1[H])C([H])([H])* 0.000 description 1
- DKFVEDKCRIZEEM-UHFFFAOYSA-N 3-(1h-imidazol-5-yl)propan-1-ol Chemical compound OCCCC1=CNC=N1 DKFVEDKCRIZEEM-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- RDXPZEOZOFBBAJ-UHFFFAOYSA-N 3-(furan-2-yl)propan-1-ol Chemical compound OCCCC1=CC=CO1 RDXPZEOZOFBBAJ-UHFFFAOYSA-N 0.000 description 1
- LCSHOKGEMMNVDH-UHFFFAOYSA-N 3-[3-(4-chlorophenyl)-1h-pyrazol-5-yl]propan-1-ol Chemical compound N1C(CCCO)=CC(C=2C=CC(Cl)=CC=2)=N1 LCSHOKGEMMNVDH-UHFFFAOYSA-N 0.000 description 1
- KWFHSBMVLYCBQP-UHFFFAOYSA-N 3-benzylpyrrolidin-2-one Chemical compound O=C1NCCC1CC1=CC=CC=C1 KWFHSBMVLYCBQP-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- XWNQUIUEIJAFNS-UHFFFAOYSA-N 3-butyl-7-prop-2-enylpurine-2,6-dione Chemical compound O=C1NC(=O)N(CCCC)C2=C1N(CC=C)C=N2 XWNQUIUEIJAFNS-UHFFFAOYSA-N 0.000 description 1
- FCFUUHLDUIAJKW-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[3-(phenoxymethyl)-1,2,4-oxadiazol-5-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(ON=1)=NC=1COC1=CC=CC=C1 FCFUUHLDUIAJKW-UHFFFAOYSA-N 0.000 description 1
- SGKCWNDDAXHJSK-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[3-(pyridin-3-ylmethyl)-1,2,4-oxadiazol-5-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(ON=1)=NC=1CC1=CC=CN=C1 SGKCWNDDAXHJSK-UHFFFAOYSA-N 0.000 description 1
- MSMOBSBJKRVSGB-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[3-(thiophen-2-ylmethyl)-1,2,4-oxadiazol-5-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(ON=1)=NC=1CC1=CC=CS1 MSMOBSBJKRVSGB-UHFFFAOYSA-N 0.000 description 1
- KBPQEFLFUCZARZ-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[3-[(2,3-dichlorophenyl)methyl]-1,2,4-oxadiazol-5-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(ON=1)=NC=1CC1=CC=CC(Cl)=C1Cl KBPQEFLFUCZARZ-UHFFFAOYSA-N 0.000 description 1
- YGQYQBXTIBYAJM-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[3-[(2,3-difluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(ON=1)=NC=1CC1=CC=CC(F)=C1F YGQYQBXTIBYAJM-UHFFFAOYSA-N 0.000 description 1
- BCKSWACYLZDFGU-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[3-[(2,5-difluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(ON=1)=NC=1CC1=CC(F)=CC=C1F BCKSWACYLZDFGU-UHFFFAOYSA-N 0.000 description 1
- BZCOSBOUIVDVEH-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[3-[(3,4-dichlorophenyl)methyl]-1,2,4-oxadiazol-5-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(ON=1)=NC=1CC1=CC=C(Cl)C(Cl)=C1 BZCOSBOUIVDVEH-UHFFFAOYSA-N 0.000 description 1
- IGQDZZCEUUHTMP-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[3-[(3,4-difluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(ON=1)=NC=1CC1=CC=C(F)C(F)=C1 IGQDZZCEUUHTMP-UHFFFAOYSA-N 0.000 description 1
- HNQSNBGGHHBXGL-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[3-[(3,5-dichlorophenyl)methyl]-1,2,4-oxadiazol-5-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(ON=1)=NC=1CC1=CC(Cl)=CC(Cl)=C1 HNQSNBGGHHBXGL-UHFFFAOYSA-N 0.000 description 1
- BOUBFNXXVDZXAM-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[3-[(3-ethoxy-4-hydroxyphenyl)methyl]-1,2,4-oxadiazol-5-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(ON=1)=NC=1CC1=CC=C(O)C(OCC)=C1 BOUBFNXXVDZXAM-UHFFFAOYSA-N 0.000 description 1
- YCOXYSGQUVWCRF-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[3-[(4-hydroxyphenyl)methyl]-1,2,4-oxadiazol-5-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(ON=1)=NC=1CC1=CC=C(O)C=C1 YCOXYSGQUVWCRF-UHFFFAOYSA-N 0.000 description 1
- GIFZQKYDQASWGV-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[3-[(4-methyl-1,3-thiazol-2-yl)methyl]-1,2,4-oxadiazol-5-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(ON=1)=NC=1CC1=NC(C)=CS1 GIFZQKYDQASWGV-UHFFFAOYSA-N 0.000 description 1
- JYSUEVTYUOMXFW-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[3-[[3-(trifluoromethyl)pyrazol-1-yl]methyl]-1,2,4-oxadiazol-5-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(ON=1)=NC=1CN1C=CC(C(F)(F)F)=N1 JYSUEVTYUOMXFW-UHFFFAOYSA-N 0.000 description 1
- WVZUGQXOUILJSJ-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[5-[(2,4,6-trifluorophenyl)methyl]tetrazol-2-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCN(N=1)N=NC=1CC1=C(F)C=C(F)C=C1F WVZUGQXOUILJSJ-UHFFFAOYSA-N 0.000 description 1
- SEHPYUWEVUKJCH-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[5-[(2,4-difluorophenyl)methyl]tetrazol-2-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCN(N=1)N=NC=1CC1=CC=C(F)C=C1F SEHPYUWEVUKJCH-UHFFFAOYSA-N 0.000 description 1
- MPQDAFOFNSGSSS-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[5-[(2,6-difluorophenyl)methyl]tetrazol-2-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCN(N=1)N=NC=1CC1=C(F)C=CC=C1F MPQDAFOFNSGSSS-UHFFFAOYSA-N 0.000 description 1
- FDZGRGPVSKLPGJ-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[5-[(2-chlorophenyl)methyl]tetrazol-2-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCN(N=1)N=NC=1CC1=CC=CC=C1Cl FDZGRGPVSKLPGJ-UHFFFAOYSA-N 0.000 description 1
- DACUWQNTHLDUCC-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[5-[(3,4-dichlorophenyl)methyl]tetrazol-2-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCN(N=1)N=NC=1CC1=CC=C(Cl)C(Cl)=C1 DACUWQNTHLDUCC-UHFFFAOYSA-N 0.000 description 1
- SMQHYLMPPHVJBO-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[5-[(3,4-difluorophenyl)methyl]tetrazol-2-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCN(N=1)N=NC=1CC1=CC=C(F)C(F)=C1 SMQHYLMPPHVJBO-UHFFFAOYSA-N 0.000 description 1
- ZCSSITAZPYEESW-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[5-[(3-chloro-2-methoxyphenyl)methyl]-1,2,4-oxadiazol-3-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(N=1)=NOC=1CC1=CC=CC(Cl)=C1OC ZCSSITAZPYEESW-UHFFFAOYSA-N 0.000 description 1
- IDNBRWJGPKRPJR-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[5-[(3-chloro-4-hydroxyphenyl)methyl]-1,2,4-oxadiazol-3-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(N=1)=NOC=1CC1=CC=C(O)C(Cl)=C1 IDNBRWJGPKRPJR-UHFFFAOYSA-N 0.000 description 1
- NSZCWMIUOKUBQL-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[5-[(3-chlorophenyl)methyl]-1,2,4-oxadiazol-3-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(N=1)=NOC=1CC1=CC=CC(Cl)=C1 NSZCWMIUOKUBQL-UHFFFAOYSA-N 0.000 description 1
- KMPHFCSKVRYAJO-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[5-[(3-chlorophenyl)methyl]tetrazol-2-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCN(N=1)N=NC=1CC1=CC=CC(Cl)=C1 KMPHFCSKVRYAJO-UHFFFAOYSA-N 0.000 description 1
- VKMAHLLSKJEZQR-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[5-[(4-chlorophenyl)methyl]tetrazol-2-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCN(N=1)N=NC=1CC1=CC=C(Cl)C=C1 VKMAHLLSKJEZQR-UHFFFAOYSA-N 0.000 description 1
- UQWJCHMUPSMPFD-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[5-[[2-(trifluoromethoxy)phenyl]methyl]tetrazol-2-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCN(N=1)N=NC=1CC1=CC=CC=C1OC(F)(F)F UQWJCHMUPSMPFD-UHFFFAOYSA-N 0.000 description 1
- DQGBUGMHCBMBMW-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[5-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]tetrazol-2-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCN(N=1)N=NC=1CC1=C(F)C=CC=C1C(F)(F)F DQGBUGMHCBMBMW-UHFFFAOYSA-N 0.000 description 1
- URBJWMTXLISHDM-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[5-[[3-(trifluoromethoxy)phenyl]methyl]tetrazol-2-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCN(N=1)N=NC=1CC1=CC=CC(OC(F)(F)F)=C1 URBJWMTXLISHDM-UHFFFAOYSA-N 0.000 description 1
- OFOPEFNNAVMIBB-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[5-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]tetrazol-2-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCN(N=1)N=NC=1CC1=CC=C(F)C(C(F)(F)F)=C1 OFOPEFNNAVMIBB-UHFFFAOYSA-N 0.000 description 1
- DPMSSEFOTCETNR-UHFFFAOYSA-N 3-butyl-8-chloro-1-[4-(2-oxo-3-phenylimidazolidin-1-yl)butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCN(C1=O)CCN1C1=CC=CC=C1 DPMSSEFOTCETNR-UHFFFAOYSA-N 0.000 description 1
- LRAHVHYSOGUZLO-UHFFFAOYSA-N 3-butyl-8-chloro-1-[4-(2-oxo-3-phenylpyrrolidin-1-yl)butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCN(C1=O)CCC1C1=CC=CC=C1 LRAHVHYSOGUZLO-UHFFFAOYSA-N 0.000 description 1
- MEUUBJKJPLJTLP-UHFFFAOYSA-N 3-butyl-8-chloro-1-[4-(5-oxo-4-phenyltetrazol-1-yl)butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCN(C1=O)N=NN1C1=CC=CC=C1 MEUUBJKJPLJTLP-UHFFFAOYSA-N 0.000 description 1
- NXWRTJLMPYJBCF-UHFFFAOYSA-N 3-butyl-8-chloro-1-[4-(5-phenyltetrazol-2-yl)butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCN(N=1)N=NC=1C1=CC=CC=C1 NXWRTJLMPYJBCF-UHFFFAOYSA-N 0.000 description 1
- WKFSWUXKCPTWGO-UHFFFAOYSA-N 3-butyl-8-chloro-1-[4-(5-pyrimidin-2-yl-1,2,4-oxadiazol-3-yl)butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(N=1)=NOC=1C1=NC=CC=N1 WKFSWUXKCPTWGO-UHFFFAOYSA-N 0.000 description 1
- JYPVTADIRHRAPL-UHFFFAOYSA-N 3-butyl-8-chloro-1-[4-(5-thiophen-3-yl-1,2,4-oxadiazol-3-yl)butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(N=1)=NOC=1C=1C=CSC=1 JYPVTADIRHRAPL-UHFFFAOYSA-N 0.000 description 1
- RNSCNZKFPPKZAH-UHFFFAOYSA-N 3-butyl-8-chloro-1-[4-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(ON=1)=NC=1C1=CC=C(F)C=C1 RNSCNZKFPPKZAH-UHFFFAOYSA-N 0.000 description 1
- BSVZOIRASAHGTJ-UHFFFAOYSA-N 3-butyl-8-chloro-1-[4-[3-(4-hydroxyphenyl)-1,2,4-oxadiazol-5-yl]butyl]-7H-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(ON=1)=NC=1C1=CC=C(O)C=C1 BSVZOIRASAHGTJ-UHFFFAOYSA-N 0.000 description 1
- QDWFLVJVKWHSCX-UHFFFAOYSA-N 3-butyl-8-chloro-1-[4-[5-(1H-imidazol-2-yl)-1,2,4-oxadiazol-3-yl]butyl]-7H-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(N=1)=NOC=1C1=NC=CN1 QDWFLVJVKWHSCX-UHFFFAOYSA-N 0.000 description 1
- XIIBNJUOPOOKMC-UHFFFAOYSA-N 3-butyl-8-chloro-1-[4-[5-(1h-indazol-3-yl)-1,2,4-oxadiazol-3-yl]butyl]-7h-purine-2,6-dione Chemical compound C1=CC=C2C(C=3ON=C(N=3)CCCCN3C(=O)C=4NC(Cl)=NC=4N(C3=O)CCCC)=NNC2=C1 XIIBNJUOPOOKMC-UHFFFAOYSA-N 0.000 description 1
- WWLQINBSDCSKAF-UHFFFAOYSA-N 3-butyl-8-chloro-1-[4-[5-(1h-indol-6-yl)-1,2,4-oxadiazol-3-yl]butyl]-7h-purine-2,6-dione Chemical compound C1=C2C=CNC2=CC(C=2ON=C(N=2)CCCCN2C(=O)C=3NC(Cl)=NC=3N(C2=O)CCCC)=C1 WWLQINBSDCSKAF-UHFFFAOYSA-N 0.000 description 1
- GUJCHUNDVJOVQL-UHFFFAOYSA-N 3-butyl-8-chloro-1-[4-[5-(2-chloro-6-fluorophenyl)-1,2,4-oxadiazol-3-yl]butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(N=1)=NOC=1C1=C(F)C=CC=C1Cl GUJCHUNDVJOVQL-UHFFFAOYSA-N 0.000 description 1
- DITJVYDFZFIWAO-UHFFFAOYSA-N 3-butyl-8-chloro-1-[4-[5-(2-chlorophenyl)tetrazol-2-yl]butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCN(N=1)N=NC=1C1=CC=CC=C1Cl DITJVYDFZFIWAO-UHFFFAOYSA-N 0.000 description 1
- CDBLRQHTGGAEQC-UHFFFAOYSA-N 3-butyl-8-chloro-1-[4-[5-(2-chlorothiophen-3-yl)-1,2,4-oxadiazol-3-yl]butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(N=1)=NOC=1C=1C=CSC=1Cl CDBLRQHTGGAEQC-UHFFFAOYSA-N 0.000 description 1
- QAWWLCWLQWSXIH-UHFFFAOYSA-N 3-butyl-8-chloro-1-[4-[5-(2-fluoro-4-hydroxyphenyl)-1,2,4-oxadiazol-3-yl]butyl]-7H-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(N=1)=NOC=1C1=CC=C(O)C=C1F QAWWLCWLQWSXIH-UHFFFAOYSA-N 0.000 description 1
- XFCQKBMPLMRXMJ-UHFFFAOYSA-N 3-butyl-8-chloro-1-[4-[5-(3-methylpyridin-2-yl)-1,2,4-oxadiazol-3-yl]butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(N=1)=NOC=1C1=NC=CC=C1C XFCQKBMPLMRXMJ-UHFFFAOYSA-N 0.000 description 1
- KGQOCSRDFBBYMW-UHFFFAOYSA-N 3-butyl-8-chloro-1-[4-[5-(4-chloropyridin-2-yl)-1,2,4-oxadiazol-3-yl]butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(N=1)=NOC=1C1=CC(Cl)=CC=N1 KGQOCSRDFBBYMW-UHFFFAOYSA-N 0.000 description 1
- LXUSRVAAVXLQDE-UHFFFAOYSA-N 3-butyl-8-chloro-1-[4-[5-(4-hydroxyphenyl)-1,2,4-oxadiazol-3-yl]butyl]-7H-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(N=1)=NOC=1C1=CC=C(O)C=C1 LXUSRVAAVXLQDE-UHFFFAOYSA-N 0.000 description 1
- FRZPUVZSFPNQBA-UHFFFAOYSA-N 3-butyl-8-chloro-1-[4-[5-(4-methoxyphenyl)-1,2,4-oxadiazol-3-yl]butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(N=1)=NOC=1C1=CC=C(OC)C=C1 FRZPUVZSFPNQBA-UHFFFAOYSA-N 0.000 description 1
- DHYLVBNVSVTSMN-UHFFFAOYSA-N 3-butyl-8-chloro-1-[4-[5-(5-hydroxypyridin-2-yl)-1,2,4-oxadiazol-3-yl]butyl]-7H-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(N=1)=NOC=1C1=CC=C(O)C=N1 DHYLVBNVSVTSMN-UHFFFAOYSA-N 0.000 description 1
- ZJTIYTFMTTXPMK-UHFFFAOYSA-N 3-butyl-8-chloro-1-[4-[5-(6-methylpyridin-2-yl)-1,2,4-oxadiazol-3-yl]butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(N=1)=NOC=1C1=CC=CC(C)=N1 ZJTIYTFMTTXPMK-UHFFFAOYSA-N 0.000 description 1
- YJNBKJJUWHXLJC-UHFFFAOYSA-N 3-butyl-8-chloro-1-[4-[5-(6-oxo-1h-pyridin-2-yl)-1,2,4-oxadiazol-3-yl]butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(N=1)=NOC=1C1=CC=CC(=O)N1 YJNBKJJUWHXLJC-UHFFFAOYSA-N 0.000 description 1
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 1
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
- LMHIBYREWJHKNZ-UHFFFAOYSA-N 3-methylpyridine-2-carboxylic acid Chemical compound CC1=CC=CN=C1C(O)=O LMHIBYREWJHKNZ-UHFFFAOYSA-N 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- WRCVXXZOFYATBD-UHFFFAOYSA-N 4-(3-butyl-8-chloro-2,6-dioxo-7-prop-2-enylpurin-1-yl)butyl methanesulfonate Chemical compound O=C1N(CCCCOS(C)(=O)=O)C(=O)N(CCCC)C2=C1N(CC=C)C(Cl)=N2 WRCVXXZOFYATBD-UHFFFAOYSA-N 0.000 description 1
- ZZLCFHIKESPLTH-UHFFFAOYSA-N 4-Methylbiphenyl Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1 ZZLCFHIKESPLTH-UHFFFAOYSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- NNMYRMGMVLMQAY-UHFFFAOYSA-N 4-chloropyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC(Cl)=CC=N1 NNMYRMGMVLMQAY-UHFFFAOYSA-N 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NCXNEFKJJQAIOQ-UHFFFAOYSA-N 5-(8-chloro-2,6-dioxo-3-pentyl-7h-purin-1-yl)pentanenitrile Chemical compound O=C1N(CCCCC#N)C(=O)N(CCCCC)C2=C1NC(Cl)=N2 NCXNEFKJJQAIOQ-UHFFFAOYSA-N 0.000 description 1
- YOIOCWUSTHHAAI-UHFFFAOYSA-N 5-(8-chloro-2,6-dioxo-3-pentyl-7h-purin-1-yl)pentanoic acid Chemical compound O=C1N(CCCCC(O)=O)C(=O)N(CCCCC)C2=C1NC(Cl)=N2 YOIOCWUSTHHAAI-UHFFFAOYSA-N 0.000 description 1
- MJYFMIDWNQYYCF-UHFFFAOYSA-N 5-(8-chloro-2,6-dioxo-3-propyl-7h-purin-1-yl)pentanoic acid Chemical compound O=C1N(CCCCC(O)=O)C(=O)N(CCC)C2=C1NC(Cl)=N2 MJYFMIDWNQYYCF-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- LMPLGVYRMMTLGJ-UHFFFAOYSA-N 5-[5-[(3,4-dichlorophenyl)methyl]tetrazol-2-yl]pentan-1-ol Chemical compound OCCCCCN1N=NC(CC=2C=C(Cl)C(Cl)=CC=2)=N1 LMPLGVYRMMTLGJ-UHFFFAOYSA-N 0.000 description 1
- VZEAUAKJULSHNO-UHFFFAOYSA-N 5-benzyl-1h-1,2,4-triazole Chemical compound C=1C=CC=CC=1CC1=NC=NN1 VZEAUAKJULSHNO-UHFFFAOYSA-N 0.000 description 1
- RNBADEZLWRQCLW-UHFFFAOYSA-N 5-benzyl-3-(3,3-diethoxypropyl)-1,2,4-oxadiazole Chemical compound CCOC(OCC)CCC1=NOC(CC=2C=CC=CC=2)=N1 RNBADEZLWRQCLW-UHFFFAOYSA-N 0.000 description 1
- FOMJQFVXCFCFLS-UHFFFAOYSA-N 5-benzyl-5-(3,3-diethoxypropyl)-2h-1,2,4-oxadiazole Chemical compound C=1C=CC=CC=1CC1(CCC(OCC)OCC)ONC=N1 FOMJQFVXCFCFLS-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- FOADVIMBBUOSPN-UHFFFAOYSA-N 8-chloro-1-(2-hydroxy-6-phenylhexyl)-3-pentyl-7-prop-2-enylpurine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)N(CC=C)C=2C(=O)N1CC(O)CCCCC1=CC=CC=C1 FOADVIMBBUOSPN-UHFFFAOYSA-N 0.000 description 1
- FADMKNMEPLFAPK-UHFFFAOYSA-N 8-chloro-1-(3-hydroxypropyl)-7-prop-2-enyl-3-(4,4,4-trifluorobutyl)purine-2,6-dione Chemical compound O=C1N(CCCO)C(=O)N(CCCC(F)(F)F)C2=C1N(CC=C)C(Cl)=N2 FADMKNMEPLFAPK-UHFFFAOYSA-N 0.000 description 1
- XUBXLQYAOPFODB-UHFFFAOYSA-N 8-chloro-1-[3-(furan-2-yl)propyl]-3-pentyl-7h-purine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC1=CC=CO1 XUBXLQYAOPFODB-UHFFFAOYSA-N 0.000 description 1
- XSVRPPBAQHFSPE-UHFFFAOYSA-N 8-chloro-1-[3-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]propyl]-3-pentyl-7h-purine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(=C1)C=NN1CC1=CC=CC(F)=C1 XSVRPPBAQHFSPE-UHFFFAOYSA-N 0.000 description 1
- XQBDTPCWJDUCIR-UHFFFAOYSA-N 8-chloro-1-[3-[1-[(4-chlorophenyl)methyl]pyrazol-4-yl]propyl]-3-pentyl-7h-purine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(=C1)C=NN1CC1=CC=C(Cl)C=C1 XQBDTPCWJDUCIR-UHFFFAOYSA-N 0.000 description 1
- CUUSUQUAABWDPS-UHFFFAOYSA-N 8-chloro-1-[3-[1-[(5-chlorothiophen-2-yl)methyl]pyrazol-4-yl]propyl]-3-pentyl-7h-purine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(=C1)C=NN1CC1=CC=C(Cl)S1 CUUSUQUAABWDPS-UHFFFAOYSA-N 0.000 description 1
- CIEOMEPFOLMBBK-UHFFFAOYSA-N 8-chloro-1-[3-[1-[(5-methyl-1,2-oxazol-3-yl)methyl]pyrazol-4-yl]propyl]-3-pentyl-7h-purine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(=C1)C=NN1CC=1C=C(C)ON=1 CIEOMEPFOLMBBK-UHFFFAOYSA-N 0.000 description 1
- PRKYGZFZNQMEAV-UHFFFAOYSA-N 8-chloro-1-[3-[3-[(2,4-difluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]propyl]-3-(3-methoxypropyl)-7h-purine-2,6-dione Chemical compound O=C1N(CCCOC)C=2N=C(Cl)NC=2C(=O)N1CCCC(ON=1)=NC=1CC1=CC=C(F)C=C1F PRKYGZFZNQMEAV-UHFFFAOYSA-N 0.000 description 1
- NZEMWCOJVHRPQF-UHFFFAOYSA-N 8-chloro-1-[3-[3-[(2,4-difluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]propyl]-3-pentyl-7h-purine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(ON=1)=NC=1CC1=CC=C(F)C=C1F NZEMWCOJVHRPQF-UHFFFAOYSA-N 0.000 description 1
- VGDBCGCONHXHHH-UHFFFAOYSA-N 8-chloro-1-[3-[3-[(2,4-difluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]propyl]-3-propyl-7h-purine-2,6-dione Chemical compound O=C1N(CCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(ON=1)=NC=1CC1=CC=C(F)C=C1F VGDBCGCONHXHHH-UHFFFAOYSA-N 0.000 description 1
- OIBKXZUBJLBJCL-UHFFFAOYSA-N 8-chloro-1-[3-[3-[(2,4-difluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]propyl]-7-prop-2-enyl-3h-purine-2,6-dione Chemical compound FC1=CC(F)=CC=C1CC1=NOC(CCCN2C(C=3N(CC=C)C(Cl)=NC=3NC2=O)=O)=N1 OIBKXZUBJLBJCL-UHFFFAOYSA-N 0.000 description 1
- FXUCIINNPCAJKS-UHFFFAOYSA-N 8-chloro-1-[3-[3-[(2,6-dichlorophenyl)methyl]-1,2,4-oxadiazol-5-yl]propyl]-3-pentyl-7h-purine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(ON=1)=NC=1CC1=C(Cl)C=CC=C1Cl FXUCIINNPCAJKS-UHFFFAOYSA-N 0.000 description 1
- CQTCEFUAUTYQOC-UHFFFAOYSA-N 8-chloro-1-[3-[3-[(3,4-dichlorophenyl)methyl]-1,2,4-oxadiazol-5-yl]propyl]-3-pentyl-7h-purine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(ON=1)=NC=1CC1=CC=C(Cl)C(Cl)=C1 CQTCEFUAUTYQOC-UHFFFAOYSA-N 0.000 description 1
- PZHARZVPCRUVRX-UHFFFAOYSA-N 8-chloro-1-[3-[3-[(3-chlorophenyl)methyl]-1,2,4-oxadiazol-5-yl]propyl]-3-pentyl-7h-purine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(ON=1)=NC=1CC1=CC=CC(Cl)=C1 PZHARZVPCRUVRX-UHFFFAOYSA-N 0.000 description 1
- ILQDANOGYPWCGC-UHFFFAOYSA-N 8-chloro-1-[3-[3-[(4-chlorophenyl)methyl]-1,2,4-oxadiazol-5-yl]propyl]-3-pentyl-7-prop-2-enylpurine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)N(CC=C)C=2C(=O)N1CCCC(ON=1)=NC=1CC1=CC=C(Cl)C=C1 ILQDANOGYPWCGC-UHFFFAOYSA-N 0.000 description 1
- LQNIYCHVACLRTE-UHFFFAOYSA-N 8-chloro-1-[3-[5-[(2,4-difluorophenyl)methyl]tetrazol-2-yl]propyl]-3-propyl-7h-purine-2,6-dione Chemical compound O=C1N(CCC)C=2N=C(Cl)NC=2C(=O)N1CCCN(N=1)N=NC=1CC1=CC=C(F)C=C1F LQNIYCHVACLRTE-UHFFFAOYSA-N 0.000 description 1
- HRLGLZVIGMGZRL-UHFFFAOYSA-N 8-chloro-1-[3-[5-[(2-chloro-4-fluorophenyl)methyl]-1,3,4-oxadiazol-2-yl]propyl]-3-(3-cyclopropylpropyl)-7h-purine-2,6-dione Chemical compound ClC1=CC(F)=CC=C1CC(O1)=NN=C1CCCN1C(=O)C(NC(Cl)=N2)=C2N(CCCC2CC2)C1=O HRLGLZVIGMGZRL-UHFFFAOYSA-N 0.000 description 1
- YMDUMWBZAQMWQU-UHFFFAOYSA-N 8-chloro-1-[3-[5-[(4-fluorophenyl)methyl]tetrazol-2-yl]propyl]-3-propyl-7h-purine-2,6-dione Chemical compound O=C1N(CCC)C=2N=C(Cl)NC=2C(=O)N1CCCN(N=1)N=NC=1CC1=CC=C(F)C=C1 YMDUMWBZAQMWQU-UHFFFAOYSA-N 0.000 description 1
- VQIMSPCWONKSBO-UHFFFAOYSA-N 8-chloro-1-[4-(3-phenyl-1,2,4-oxadiazol-5-yl)butyl]-3-propyl-7h-purine-2,6-dione Chemical compound O=C1N(CCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(ON=1)=NC=1C1=CC=CC=C1 VQIMSPCWONKSBO-UHFFFAOYSA-N 0.000 description 1
- YLFLQAQTWKIQTP-UHFFFAOYSA-N 8-chloro-1-[4-[3-(2,4-difluorophenyl)-1,2,4-oxadiazol-5-yl]butyl]-3-ethyl-7h-purine-2,6-dione Chemical compound O=C1N(CC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(ON=1)=NC=1C1=CC=C(F)C=C1F YLFLQAQTWKIQTP-UHFFFAOYSA-N 0.000 description 1
- KIMAIEVTHBQDOA-UHFFFAOYSA-N 8-chloro-1-[4-[3-(2,4-difluorophenyl)-1,2,4-oxadiazol-5-yl]butyl]-3-propyl-7h-purine-2,6-dione Chemical compound O=C1N(CCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(ON=1)=NC=1C1=CC=C(F)C=C1F KIMAIEVTHBQDOA-UHFFFAOYSA-N 0.000 description 1
- FCDRHARRQRUFMP-UHFFFAOYSA-N 8-chloro-1-[4-[3-(4-hydroxyphenyl)-1,2,4-oxadiazol-5-yl]butyl]-3-pentyl-7H-purine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(ON=1)=NC=1C1=CC=C(O)C=C1 FCDRHARRQRUFMP-UHFFFAOYSA-N 0.000 description 1
- GCKMBTOENZEXES-UHFFFAOYSA-N 8-chloro-1-[4-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]butyl]-3-pentyl-7h-purine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(N=1)=NOC=1C1=CC=CC=C1F GCKMBTOENZEXES-UHFFFAOYSA-N 0.000 description 1
- SOWLKTBRNTWYCP-UHFFFAOYSA-N 8-chloro-1-[4-[5-(2-methoxyphenyl)-1,2,4-oxadiazol-3-yl]butyl]-3-pentyl-7h-purine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(N=1)=NOC=1C1=CC=CC=C1OC SOWLKTBRNTWYCP-UHFFFAOYSA-N 0.000 description 1
- INKVDZVPUKLJLO-UHFFFAOYSA-N 8-chloro-1-[4-[5-(4-hydroxyphenyl)-1,2,4-oxadiazol-3-yl]butyl]-3-propyl-7H-purine-2,6-dione Chemical compound O=C1N(CCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(N=1)=NOC=1C1=CC=C(O)C=C1 INKVDZVPUKLJLO-UHFFFAOYSA-N 0.000 description 1
- WPKPSDKASXMGCJ-UHFFFAOYSA-N 8-chloro-1-[4-[5-(5-chloropyridin-2-yl)-1,2,4-oxadiazol-3-yl]butyl]-3-propyl-7h-purine-2,6-dione Chemical compound O=C1N(CCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(N=1)=NOC=1C1=CC=C(Cl)C=N1 WPKPSDKASXMGCJ-UHFFFAOYSA-N 0.000 description 1
- HJGBUXGDHPRRIC-UHFFFAOYSA-N 8-chloro-3-(2-methylpropyl)-1-[4-(3-pyridin-2-yl-1,2,4-oxadiazol-5-yl)butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CC(C)C)C=2N=C(Cl)NC=2C(=O)N1CCCCC(ON=1)=NC=1C1=CC=CC=N1 HJGBUXGDHPRRIC-UHFFFAOYSA-N 0.000 description 1
- ANZJFHVMRPZETI-UHFFFAOYSA-N 8-chloro-3-(3,3-dimethylbutyl)-1-(2-ethoxyethyl)-7h-purine-2,6-dione Chemical compound O=C1N(CCOCC)C(=O)N(CCC(C)(C)C)C2=C1NC(Cl)=N2 ANZJFHVMRPZETI-UHFFFAOYSA-N 0.000 description 1
- MFKNNTJVLBIKBL-UHFFFAOYSA-N 8-chloro-3-(3-methoxypropyl)-1-[4-(3-pyridin-2-yl-1,2,4-oxadiazol-5-yl)butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCOC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(ON=1)=NC=1C1=CC=CC=N1 MFKNNTJVLBIKBL-UHFFFAOYSA-N 0.000 description 1
- OYOUZDVTQOWBAP-UHFFFAOYSA-N 8-chloro-3-(4,4,4-trifluorobutyl)-1-[3-[5-[(2,4,6-trifluorophenyl)methyl]tetrazol-2-yl]propyl]-7h-purine-2,6-dione Chemical compound FC1=CC(F)=CC(F)=C1CC1=NN(CCCN2C(C=3NC(Cl)=NC=3N(CCCC(F)(F)F)C2=O)=O)N=N1 OYOUZDVTQOWBAP-UHFFFAOYSA-N 0.000 description 1
- LNTACSJSGRSMPJ-UHFFFAOYSA-N 8-chloro-3-(4-fluorobutyl)-1-[4-(5-phenyl-1,2,4-oxadiazol-3-yl)butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCCF)C=2N=C(Cl)NC=2C(=O)N1CCCCC(N=1)=NOC=1C1=CC=CC=C1 LNTACSJSGRSMPJ-UHFFFAOYSA-N 0.000 description 1
- MFPFATDJBSOTJY-UHFFFAOYSA-N 8-chloro-3-ethyl-1-[4-(3-pyridin-2-yl-1,2,4-oxadiazol-5-yl)butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(ON=1)=NC=1C1=CC=CC=N1 MFPFATDJBSOTJY-UHFFFAOYSA-N 0.000 description 1
- GEDMFKJRSLQBBH-UHFFFAOYSA-N 8-chloro-3-methyl-1-[4-(3-pyridin-2-yl-1,2,4-oxadiazol-5-yl)butyl]-7h-purine-2,6-dione Chemical compound O=C1N(C)C=2N=C(Cl)NC=2C(=O)N1CCCCC(ON=1)=NC=1C1=CC=CC=N1 GEDMFKJRSLQBBH-UHFFFAOYSA-N 0.000 description 1
- IZKDGQZMSFIIHY-UHFFFAOYSA-N 8-chloro-3-pentyl-1-[3-[1-[(2,4,6-trifluorophenyl)methyl]pyrazol-4-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(=C1)C=NN1CC1=C(F)C=C(F)C=C1F IZKDGQZMSFIIHY-UHFFFAOYSA-N 0.000 description 1
- JDEFLTXBUCXIBQ-UHFFFAOYSA-N 8-chloro-3-pentyl-1-[3-[3-(thiophen-3-ylmethyl)-1,2,4-oxadiazol-5-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(ON=1)=NC=1CC=1C=CSC=1 JDEFLTXBUCXIBQ-UHFFFAOYSA-N 0.000 description 1
- FFEXCCYMECKONZ-UHFFFAOYSA-N 8-chloro-3-pentyl-1-[4-(5-phenyl-1,2,4-oxadiazol-3-yl)butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(N=1)=NOC=1C1=CC=CC=C1 FFEXCCYMECKONZ-UHFFFAOYSA-N 0.000 description 1
- RXLGTYYXBOERBY-UHFFFAOYSA-N 8-chloro-3-pentyl-1-[4-(5-pyridin-2-yl-1,2,4-oxadiazol-3-yl)butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(N=1)=NOC=1C1=CC=CC=N1 RXLGTYYXBOERBY-UHFFFAOYSA-N 0.000 description 1
- AIGGNNMFQVACBK-UHFFFAOYSA-N 8-chloro-3-pentyl-1-[4-[5-(1,3-thiazol-2-yl)-1,2,4-oxadiazol-3-yl]butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(N=1)=NOC=1C1=NC=CS1 AIGGNNMFQVACBK-UHFFFAOYSA-N 0.000 description 1
- KZRPTYICJBAMOH-UHFFFAOYSA-N 8-chloro-3-propyl-1-[3-[5-(thiophen-2-ylmethyl)tetrazol-2-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCC)C=2N=C(Cl)NC=2C(=O)N1CCCN(N=1)N=NC=1CC1=CC=CS1 KZRPTYICJBAMOH-UHFFFAOYSA-N 0.000 description 1
- ZHQSODNDVFYUIH-UHFFFAOYSA-N 8-chloro-3-propyl-1-[3-[5-[(2,4,6-trifluorophenyl)methyl]tetrazol-2-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCC)C=2N=C(Cl)NC=2C(=O)N1CCCN(N=1)N=NC=1CC1=C(F)C=C(F)C=C1F ZHQSODNDVFYUIH-UHFFFAOYSA-N 0.000 description 1
- WMEPYDPFJKRQLH-UHFFFAOYSA-N 8-chloro-3-propyl-1-[4-(3-pyridin-2-yl-1,2,4-oxadiazol-5-yl)butyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCC)C=2N=C(Cl)NC=2C(=O)N1CCCCC(ON=1)=NC=1C1=CC=CC=N1 WMEPYDPFJKRQLH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- JHOLLPHFTVXEBL-BQYQJAHWSA-N C(C)(C)(OC(=O)/N=N/C(=O)O)C Chemical compound C(C)(C)(OC(=O)/N=N/C(=O)O)C JHOLLPHFTVXEBL-BQYQJAHWSA-N 0.000 description 1
- ZJKUJQMROYKLQE-UHFFFAOYSA-N CCO.CC[Na] Chemical compound CCO.CC[Na] ZJKUJQMROYKLQE-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101100348617 Candida albicans (strain SC5314 / ATCC MYA-2876) NIK1 gene Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 102100032404 Cholinesterase Human genes 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000943274 Homo sapiens Cholinesterase Proteins 0.000 description 1
- 101100177268 Homo sapiens HCAR3 gene Proteins 0.000 description 1
- 101000799554 Homo sapiens Protein AATF Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100268906 Mus musculus Acox1 gene Proteins 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 108700010041 Nicotinic acid receptor Proteins 0.000 description 1
- 102000010410 Nogo Proteins Human genes 0.000 description 1
- 108010077641 Nogo Proteins Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- RFFFKMOABOFIDF-UHFFFAOYSA-N Pentanenitrile Chemical compound CCCCC#N RFFFKMOABOFIDF-UHFFFAOYSA-N 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100007329 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS1 gene Proteins 0.000 description 1
- 102100037580 Sesquipedalian-1 Human genes 0.000 description 1
- 101710169844 Sesquipedalian-1 Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- WLYPBMBWKYALCG-UHFFFAOYSA-N [2,4-bis(trifluoromethyl)phenyl]boronic acid Chemical group OB(O)C1=CC=C(C(F)(F)F)C=C1C(F)(F)F WLYPBMBWKYALCG-UHFFFAOYSA-N 0.000 description 1
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- UELITFHSCLAHKR-UHFFFAOYSA-N acibenzolar-S-methyl Chemical compound CSC(=O)C1=CC=CC2=C1SN=N2 UELITFHSCLAHKR-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- DULCUDSUACXJJC-UHFFFAOYSA-N benzeneacetic acid ethyl ester Natural products CCOC(=O)CC1=CC=CC=C1 DULCUDSUACXJJC-UHFFFAOYSA-N 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019846 buffering salt Nutrition 0.000 description 1
- FCCCRBDJBTVFSJ-UHFFFAOYSA-N butanehydrazide Chemical compound CCCC(=O)NN FCCCRBDJBTVFSJ-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- WJYHCYBNUJVCEH-UHFFFAOYSA-N cyclohexane;ethoxyethane Chemical compound CCOCC.C1CCCCC1 WJYHCYBNUJVCEH-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000005077 diacylhydrazine group Chemical group 0.000 description 1
- 150000008037 diacylhydrazines Chemical class 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 125000004188 dichlorophenyl group Chemical group 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 125000004212 difluorophenyl group Chemical group 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000008497 endothelial barrier function Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- MVMPKHJUPNWMDZ-UHFFFAOYSA-N ethyl 1,3-thiazole-2-carboxylate Chemical compound CCOC(=O)C1=NC=CS1 MVMPKHJUPNWMDZ-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- OYSLMAQEMAJMCL-UHFFFAOYSA-N ethyl thiophene-3-carboxylate Chemical compound CCOC(=O)C=1C=CSC=1 OYSLMAQEMAJMCL-UHFFFAOYSA-N 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000006138 lithiation reaction Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- ZSRCGGBALFGALF-VOTSOKGWSA-N methyl (e)-3-[4-(bromomethyl)phenyl]prop-2-enoate Chemical compound COC(=O)\C=C\C1=CC=C(CBr)C=C1 ZSRCGGBALFGALF-VOTSOKGWSA-N 0.000 description 1
- YQBDQZNYQADZFR-UHFFFAOYSA-N methyl 5-(8-chloro-2,6-dioxo-3-pentyl-7h-purin-1-yl)pentanoate Chemical compound O=C1N(CCCCC(=O)OC)C(=O)N(CCCCC)C2=C1NC(Cl)=N2 YQBDQZNYQADZFR-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- LAFUFQCAOPMOBV-UHFFFAOYSA-N n-[3-[[5-[3-(3-butyl-8-chloro-2,6-dioxo-7h-purin-1-yl)propyl]-1,2,4-oxadiazol-3-yl]methyl]phenyl]acetamide Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCC(ON=1)=NC=1CC1=CC=CC(NC(C)=O)=C1 LAFUFQCAOPMOBV-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000009935 nitrosation Effects 0.000 description 1
- 238000007034 nitrosation reaction Methods 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000004866 oxadiazoles Chemical class 0.000 description 1
- IVMHDOBGNQOUHO-UHFFFAOYSA-N oxathiane Chemical compound C1CCSOC1 IVMHDOBGNQOUHO-UHFFFAOYSA-N 0.000 description 1
- 125000005880 oxathiolanyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- PARWUHTVGZSQPD-UHFFFAOYSA-N phenylsilane Chemical compound [SiH3]C1=CC=CC=C1 PARWUHTVGZSQPD-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- DKORSYDQYFVQNS-UHFFFAOYSA-N propyl methanesulfonate Chemical compound CCCOS(C)(=O)=O DKORSYDQYFVQNS-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical class [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- QKSQWQOAUQFORH-VAWYXSNFSA-N tert-butyl (ne)-n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)\N=N\C(=O)OC(C)(C)C QKSQWQOAUQFORH-VAWYXSNFSA-N 0.000 description 1
- LWASFOOUZTWLGH-UHFFFAOYSA-N tert-butyl n-[[2-(2-chloro-4-fluorophenyl)acetyl]amino]carbamate Chemical compound CC(C)(C)OC(=O)NNC(=O)CC1=CC=C(F)C=C1Cl LWASFOOUZTWLGH-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000004360 trifluorophenyl group Chemical group 0.000 description 1
- 125000000725 trifluoropropyl group Chemical group [H]C([H])(*)C([H])([H])C(F)(F)F 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0516464A GB0516464D0 (en) | 2005-08-10 | 2005-08-10 | Novel compounds |
| GB0607736A GB0607736D0 (en) | 2006-04-19 | 2006-04-19 | Novel compounds |
| GB0614569A GB0614569D0 (en) | 2006-07-21 | 2006-07-21 | Novel compounds |
| PCT/EP2006/007865 WO2007017261A1 (en) | 2005-08-10 | 2006-08-08 | Xanthine derivatives as selective hm74a agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200800555A1 EA200800555A1 (ru) | 2008-08-29 |
| EA014556B1 true EA014556B1 (ru) | 2010-12-30 |
Family
ID=37189397
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200800555A EA014556B1 (ru) | 2005-08-10 | 2006-08-08 | Производные ксантина в качестве селективных агонистов hm74a |
| EA200800564A EA200800564A1 (ru) | 2005-08-10 | 2006-08-08 | Производные ксантина как селективные агонисты нм74а |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200800564A EA200800564A1 (ru) | 2005-08-10 | 2006-08-08 | Производные ксантина как селективные агонисты нм74а |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US8143264B2 (enExample) |
| EP (3) | EP2272848B1 (enExample) |
| JP (2) | JP2009504592A (enExample) |
| KR (2) | KR20080038396A (enExample) |
| AR (1) | AR055369A1 (enExample) |
| AT (1) | ATE487719T1 (enExample) |
| AU (2) | AU2006278216A1 (enExample) |
| BR (2) | BRPI0614270A2 (enExample) |
| CA (2) | CA2618963A1 (enExample) |
| CR (2) | CR9748A (enExample) |
| CY (1) | CY1111757T1 (enExample) |
| DE (1) | DE602006018151D1 (enExample) |
| DK (1) | DK1912991T3 (enExample) |
| EA (2) | EA014556B1 (enExample) |
| ES (1) | ES2401128T3 (enExample) |
| HR (1) | HRP20100725T1 (enExample) |
| IL (2) | IL189083A0 (enExample) |
| MA (2) | MA29693B1 (enExample) |
| MX (2) | MX2008001929A (enExample) |
| MY (1) | MY142067A (enExample) |
| NO (2) | NO20081211L (enExample) |
| NZ (1) | NZ565494A (enExample) |
| PE (1) | PE20070405A1 (enExample) |
| PL (1) | PL1912991T3 (enExample) |
| PT (1) | PT1912991E (enExample) |
| SI (1) | SI1912991T1 (enExample) |
| TW (1) | TW200800217A (enExample) |
| WO (2) | WO2007017261A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7495005B2 (en) * | 2002-08-22 | 2009-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
| CA2556073C (en) * | 2004-02-14 | 2012-01-10 | Smithkline Beecham Corporation | 8-chloro-1,3-disubstituted xanthine derivatives as hm74a receptor modulators |
| DE102004030502A1 (de) | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
| US8143264B2 (en) * | 2005-08-10 | 2012-03-27 | Glaxosmithkline Llc | Xanthine derivatives as selective HM74A agonists |
| US7511050B2 (en) | 2006-06-23 | 2009-03-31 | Incyte Corporation | Purinone derivatives as HM74A agonists |
| AR061626A1 (es) | 2006-06-23 | 2008-09-10 | Incyte Corp | Derivados de purinona como agonistas de hm74a |
| JP2010500300A (ja) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| DK2370440T3 (en) | 2008-12-08 | 2014-12-08 | Glaxosmithkline Llc | 8-Chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dion2-amino-2- (hydroxymethyl) -1,3-propandiolanhydrat for the treatment of diseases |
| SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| KR101799429B1 (ko) | 2010-05-03 | 2017-11-21 | 에스케이바이오팜 주식회사 | 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물 |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| PH12013500301A1 (en) * | 2010-08-16 | 2013-03-25 | Boehringer Ingelheim Int | Oxadiazole inhibitors of leukotriene production |
| EP2619196B1 (en) * | 2010-09-23 | 2015-09-16 | Boehringer Ingelheim International GmbH | Oxadiazole inhibitors of leukotriene production |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013178572A1 (en) * | 2012-05-30 | 2013-12-05 | F. Hoffmann-La Roche Ag | Triazolo compounds as pde10 inhibitors |
| MX370372B (es) * | 2013-03-15 | 2019-12-11 | Hydra Biosciences Inc | Xantinas sustituidas y metodos de uso de las mismas. |
| EA201591962A1 (ru) | 2013-05-10 | 2016-06-30 | Нимбус Аполло, Инк. | Ингибиторы акк и их применение |
| EP2994128B1 (en) | 2013-05-10 | 2019-01-30 | Gilead Apollo, LLC | Acc inhibitors and uses thereof |
| AU2014262638A1 (en) | 2013-05-10 | 2015-11-26 | Gilead Apollo, Llc | ACC inhibitors and uses thereof |
| AU2014262636A1 (en) | 2013-05-10 | 2015-11-26 | Gilead Apollo, Llc | ACC inhibitors and uses thereof |
| CN105646492B (zh) * | 2014-11-14 | 2019-04-09 | 中国医学科学院药物研究所 | 含五元芳杂环的取代黄嘌呤类化合物及其制备方法和用途 |
| DE102017000359A1 (de) | 2016-08-26 | 2018-03-01 | Bihl+Wiedemann Gmbh | Diagnose-Repeater für AS-Interface Netze |
| JP7178357B2 (ja) * | 2017-03-07 | 2022-11-25 | エフ．ホフマン－ラ ロシュ アーゲー | オキサジアゾール一過性受容器電位チャネル阻害剤 |
| BR112021002207A2 (pt) | 2018-08-10 | 2021-05-04 | Diapin Therapeutics, Llc | tri-peptídeos e tratamento de distúrbios metabólicos, cardiovasculares e inflamatórios |
| CN112724141A (zh) * | 2021-01-21 | 2021-04-30 | 南京艾美斐生物医药科技有限公司 | 一种gpr109a蛋白受体抑制剂及其制备和应用 |
| US20250136587A1 (en) * | 2022-02-03 | 2025-05-01 | D. E. Shaw Research, Llc | N3-substituted uracil compounds as trpa1 inhibitors |
| JP2026503850A (ja) * | 2023-01-30 | 2026-01-30 | ディー．イー．ショウ リサーチ，エルエルシー | Ｔｒｐａ１阻害剤としての二環式イミド化合物 |
| AR133217A1 (es) * | 2023-07-10 | 2025-09-10 | De Shaw Res Llc | Inhibidores de trpa1 bicíclicos y monocíclicos |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003004496A1 (en) * | 2001-07-03 | 2003-01-16 | Novo Nordisk A/S | Dpp-iv-inhibiting purine derivatives for the treatment of diabetes |
| WO2005016870A1 (en) * | 2003-08-14 | 2005-02-24 | Smithkline Beecham Corporation | 2-substituted benzoic acid derivatives as hm74a receptor agonists |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2797220A (en) | 1954-12-02 | 1957-06-25 | Univ Michigan | Substituted paraxanthines |
| GB8906792D0 (en) | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
| NZ240644A (en) | 1990-11-21 | 1994-08-26 | Smithkline Beecham Corp | Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf) |
| WO1993016699A1 (en) | 1992-02-21 | 1993-09-02 | Smithkline Beecham Corporation | Tnf inhibitors |
| CA2112239C (en) | 1992-03-04 | 2000-05-09 | James A. Bianco | Enantiomeric hydroxylated xanthine compounds |
| US6693105B1 (en) | 1992-11-16 | 2004-02-17 | Cell Therapeutics, Inc. | Hydroxyl-containing compounds |
| US5473070A (en) | 1992-11-16 | 1995-12-05 | Cell Therapeutics, Inc. | Substituted long chain alcohol xanthine compounds |
| US6469017B1 (en) | 1998-01-16 | 2002-10-22 | Cell Therapeutics, Inc. | Method of inhibiting interleukin-12 signaling |
| US5780476A (en) | 1992-11-16 | 1998-07-14 | Cell Therapeutics, Inc. | Hydroxyl-containing xanthine compounds |
| IL109161A0 (en) | 1993-03-31 | 1994-06-24 | Cell Therapeutics Inc | Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same |
| US5670506A (en) | 1993-04-05 | 1997-09-23 | Cell Therapeutics, Inc. | Halogen, isothiocyanate or azide substituted xanthines |
| AU6702894A (en) | 1993-04-09 | 1994-11-08 | Cell Therapeutics, Inc. | Ring-substituted cell signaling inhibitors |
| WO1995020589A1 (en) | 1994-01-28 | 1995-08-03 | Cell Therapeutics, Inc. | Cell signaling inhibitors |
| JPH09511496A (ja) | 1994-02-18 | 1997-11-18 | セル・セラピューティックス・インコーポレーテッド | 細胞内メッセンジャー |
| US6780865B1 (en) | 1994-02-18 | 2004-08-24 | Cell Therapeutics, Inc. | Compounds having selective hydrolytic potentials |
| US6103730A (en) | 1994-03-24 | 2000-08-15 | Cell Therapeutics, Inc. | Amine substituted compounds |
| US6878715B1 (en) | 1994-02-18 | 2005-04-12 | Cell Therapeutics, Inc. | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same |
| US5807861A (en) | 1994-03-24 | 1998-09-15 | Cell Therapeutics, Inc. | Amine substituted xanthinyl compounds |
| US6323201B1 (en) * | 1994-12-29 | 2001-11-27 | The Regents Of The University Of California | Compounds for inhibition of ceramide-mediated signal transduction |
| WO2000061583A1 (en) | 1995-06-07 | 2000-10-19 | Cell Therapeutics, Inc. | Xanthine derivatives and analogs as cell signaling inhibitors |
| AR015966A1 (es) | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
| US20030207901A1 (en) | 1999-07-27 | 2003-11-06 | Cell Therapeutics, Inc. | Hydroxyl-containing compounds |
| US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
| US6586429B2 (en) * | 2000-11-29 | 2003-07-01 | Cell Therapeutics, Inc. | Tricyclic fused xanthine compounds and their uses |
| SI1953162T1 (sl) | 2001-02-24 | 2012-09-28 | Boehringer Ingelheim Pharma | Ksantinski derivati, njihova priprava in njihova uporaba kot zdravila |
| EP1377834A2 (en) | 2001-04-11 | 2004-01-07 | Glaxo Group Limited | Medicaments which are modulators of hm74 and/or hm74a activity |
| DE60304911D1 (de) | 2002-02-25 | 2006-06-08 | Eisai Co Ltd | Xanthin-Derivate als DPP-IV-Inhibitoren |
| US7482337B2 (en) | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| CN1227492C (zh) * | 2003-03-11 | 2005-11-16 | 张跃 | 一种吸收式空调主体 |
| CA2556073C (en) * | 2004-02-14 | 2012-01-10 | Smithkline Beecham Corporation | 8-chloro-1,3-disubstituted xanthine derivatives as hm74a receptor modulators |
| WO2006045564A1 (en) * | 2004-10-22 | 2006-05-04 | Smithkline Beecham Corporation | Xanthine derivatives with hm74a receptor activity |
| WO2006045565A1 (en) * | 2004-10-22 | 2006-05-04 | Smithkline Beecham Corporation | Xanthine derivatives with hm74a receptor activity |
| US20090209561A1 (en) * | 2004-10-22 | 2009-08-20 | Richard Jonathan Daniel Hatley | Xanthine Derivatives with HM74A Receptor Activity |
| EP1848699A1 (en) | 2005-02-14 | 2007-10-31 | Smithkline Beecham Corporation | Anthranilic acid derivatives as hm74a receptor agonists |
| US8143264B2 (en) * | 2005-08-10 | 2012-03-27 | Glaxosmithkline Llc | Xanthine derivatives as selective HM74A agonists |
| GB0516462D0 (en) * | 2005-08-10 | 2005-09-14 | Smithkline Beecham Corp | Novel compounds |
| DE102008009758A1 (de) * | 2008-02-18 | 2009-08-20 | Beiersdorf Ag | Verwendung von 3-(4-Hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-propan-1-on zur verbesserten Hautkonturierung bzw. gegen Cellulite |
| DK2370440T3 (en) | 2008-12-08 | 2014-12-08 | Glaxosmithkline Llc | 8-Chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dion2-amino-2- (hydroxymethyl) -1,3-propandiolanhydrat for the treatment of diseases |
-
2006
- 2006-08-08 US US12/063,434 patent/US8143264B2/en not_active Expired - Fee Related
- 2006-08-08 HR HR20100725T patent/HRP20100725T1/hr unknown
- 2006-08-08 PT PT06763016T patent/PT1912991E/pt unknown
- 2006-08-08 AU AU2006278216A patent/AU2006278216A1/en not_active Abandoned
- 2006-08-08 MX MX2008001929A patent/MX2008001929A/es not_active Application Discontinuation
- 2006-08-08 JP JP2008525475A patent/JP2009504592A/ja not_active Withdrawn
- 2006-08-08 KR KR1020087005724A patent/KR20080038396A/ko not_active Withdrawn
- 2006-08-08 DK DK06763016.0T patent/DK1912991T3/da active
- 2006-08-08 PE PE2006000963A patent/PE20070405A1/es not_active Application Discontinuation
- 2006-08-08 PL PL06763016T patent/PL1912991T3/pl unknown
- 2006-08-08 CA CA002618963A patent/CA2618963A1/en not_active Abandoned
- 2006-08-08 WO PCT/EP2006/007865 patent/WO2007017261A1/en not_active Ceased
- 2006-08-08 BR BRPI0614270-2A patent/BRPI0614270A2/pt not_active IP Right Cessation
- 2006-08-08 JP JP2008525474A patent/JP5112316B2/ja not_active Expired - Fee Related
- 2006-08-08 TW TW095128952A patent/TW200800217A/zh unknown
- 2006-08-08 AT AT06763016T patent/ATE487719T1/de active
- 2006-08-08 SI SI200630916T patent/SI1912991T1/sl unknown
- 2006-08-08 AU AU2006278215A patent/AU2006278215A1/en not_active Abandoned
- 2006-08-08 DE DE602006018151T patent/DE602006018151D1/de not_active Expired - Lifetime
- 2006-08-08 US US12/063,432 patent/US20100179128A1/en not_active Abandoned
- 2006-08-08 ES ES10172674T patent/ES2401128T3/es not_active Expired - Lifetime
- 2006-08-08 WO PCT/EP2006/007869 patent/WO2007017262A1/en not_active Ceased
- 2006-08-08 MX MX2008001931A patent/MX2008001931A/es active IP Right Grant
- 2006-08-08 MY MYPI20063833A patent/MY142067A/en unknown
- 2006-08-08 AR ARP060103459A patent/AR055369A1/es unknown
- 2006-08-08 EP EP10172674A patent/EP2272848B1/en not_active Expired - Lifetime
- 2006-08-08 EP EP06763016A patent/EP1912991B1/en not_active Expired - Lifetime
- 2006-08-08 EA EA200800555A patent/EA014556B1/ru not_active IP Right Cessation
- 2006-08-08 NZ NZ565494A patent/NZ565494A/en not_active IP Right Cessation
- 2006-08-08 CA CA002626723A patent/CA2626723A1/en not_active Abandoned
- 2006-08-08 EP EP06776699A patent/EP1912992A1/en not_active Withdrawn
- 2006-08-08 EA EA200800564A patent/EA200800564A1/ru unknown
- 2006-08-08 KR KR1020087005717A patent/KR20080034993A/ko not_active Ceased
- 2006-08-08 BR BRPI0615145-0A patent/BRPI0615145A2/pt not_active Application Discontinuation
-
2008
- 2008-01-28 IL IL189083A patent/IL189083A0/en unknown
- 2008-01-28 IL IL189081A patent/IL189081A0/en unknown
- 2008-02-08 MA MA30629A patent/MA29693B1/fr unknown
- 2008-02-08 MA MA30628A patent/MA29692B1/fr unknown
- 2008-02-21 CR CR9748A patent/CR9748A/es not_active Application Discontinuation
- 2008-02-21 CR CR9749A patent/CR9749A/es not_active Application Discontinuation
- 2008-03-07 NO NO20081211A patent/NO20081211L/no not_active Application Discontinuation
- 2008-03-07 NO NO20081212A patent/NO20081212L/no not_active Application Discontinuation
-
2011
- 2011-01-12 CY CY20111100033T patent/CY1111757T1/el unknown
- 2011-04-18 US US13/088,962 patent/US20110257205A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003004496A1 (en) * | 2001-07-03 | 2003-01-16 | Novo Nordisk A/S | Dpp-iv-inhibiting purine derivatives for the treatment of diabetes |
| WO2005016870A1 (en) * | 2003-08-14 | 2005-02-24 | Smithkline Beecham Corporation | 2-substituted benzoic acid derivatives as hm74a receptor agonists |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2401128T3 (es) | Derivados de xantina como agonistas selectivos de HM74A | |
| KR101275980B1 (ko) | Ｃｒｔｈ２ 수용체 길항제로서의 인돌 유도체 | |
| CA2791100C (en) | Bisaryl-bonded aryltriazolones and use thereof | |
| KR102012268B1 (ko) | 염증성 질환의 치료를 위한 신규의 다이하이드로피리미디노아이소퀴놀리논 및 그의 약학 조성물 | |
| JP4895476B2 (ja) | タキキニン受容体アンタゴニスト | |
| KR20180043837A (ko) | 페녹시메틸 유도체 | |
| JP2018515559A (ja) | ヒドロキシプリン類化合物及びその応用 | |
| CN101282977B (zh) | 作为选择性hm74a激动剂的黄嘌呤衍生物 | |
| CN103119027A (zh) | 取代的苯乙酰胺和苯丙酰胺及其用途 | |
| US20240279216A1 (en) | Novel piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same | |
| HK1146279A (en) | Xanthine derivatives as selective hm74a agonists | |
| HK1187049B (en) | Bisaryl-bonded aryltriazolones and use thereof | |
| HK1160465B (en) | Indole derivatives as crth2 receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TK4A | Corrections in published eurasian patents | ||
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |